LIFE SCIENCE SWEDEN

No 1 • 2022

INTERVIEW

"We were criticised and made out to be the bad guys"

Immunotherapy and the battle against cancer

NEWS

High ambitions for life science in Stockholm: Reach the world's top 5

SWEDISH LIFE SCIENCE INDUSTRY GUIDE

STARRING

ERIKA SPENS
ANNA RYTTER
SOFIE BROBERG
LINDA NORD
ANNA TÖRNER
ÅSA HOLMGREN

BLUNDA INTE FÖR VERKLIGHETEN.

SYNA DIN REGULATORISKA STRATEGI.

DE SVÅRASTE BESLUTEN FATTAS TIDIGT I PROCESSEN.

STOCKHOLM SVÄRDVÄGEN 23, SE-182 33, DANDERYD +46 8 755 80 80
UPPSALA RÅDHUSET, VAKSALAGATAN 2, SE-753 20, UPPSALA
LUND MEDICON VILLAGE, SCHEELEVÄGEN 8, SE-223 63, LUND
OSLO SDS NORWAY, GAUSTADALLÉEN 21, 0349 BRIGHTON, OSLO

sds Life Science

sdslifescience.com

Content



Photo: Getty Images

What can **we do for you?**

Clinical Studies
Clinical Project Management **Medical Writing**
Biometrics Regulatory Affairs **Pharmacovigilance**
Audits (GMP, GDP, GCP, GVP) Quality Assurance










Full Service Partner within Life Science Nordic
240 employees

CONTACT **US**

pharmarelations.com

PharmaRelations
The Life Science Consulting Group

Immunotherapy against cancer is still in its early stages

NO MORE THAN 10 years ago, most cancer patients were subjects for chemotherapy, radiation or surgery, which are important treatments that can prolong life, but in many cases, they are also followed by pain and severe side effects.

In the last decade, another strategy against cancer has been introduced on a large scale – immunotherapy, which is not a new field of research though.

> For more than 100 years, researchers have tried to target the body's own immune system to fight cancer cells. They have occasionally been laughed at and ridiculed by the medical establishment”

FOR MORE THAN 100 YEARS, researchers have tried to target the body's own immune system to fight cancer cells. They have occasionally been laughed at and ridiculed by the medical establishment, as the American author Charles Graeber describes in his recommendable book *The Breakthrough* (2019). In some cases, the criticism was justified, as researchers, obsessed with the idea of making the immune system fight cancer, would perform experiments, which would hardly meet the present requirements for a modern ethics test. However, from our perspective today, we can sum it up with the old saying: He who laughs last laughs best.

Research in the 1990s laid the foundation for the most successful form of immunotherapy to date, checkpoint blockade, as James Alison in the United States and Tasuku Honjo in Japan began to investigate mechanisms that allowed cancer cells to deceive the body's immune response. The two scientists each found a way to release the cancer cells' "brakes" on the immune system. The rest is history.

In 2011, the first checkpoint inhibitor against malignant melanoma was approved. To their amazement, doctors could now see tumours and metastases disappear from patients' X-rays from one visit to the doctor to the next. Since then, immunotherapy has been approved for more types of cancers, and in 2018, James Allison and Tasuku Honjo received the Nobel Prize for their discoveries.

At Life Science Sweden, we often write about checkpoint inhibitors as it is an exciting development, which, despite the progress, is still in its infancy. Research and development are ongoing to ensure that more patients will respond to this type of treatment.

IN THIS ISSUE, we take a deep look into another form of immunotherapy. CAR-T therapy is a cell therapy in which white blood cells are removed from the patient's bloodstream, and a new gene, which prompts the blood cells to attack cancer cells, is inserted into the blood cells in a laboratory. The immune cells are then returned to the body to battle the cancer.

The development of this form of immunotherapy has not come as far as that of the checkpoint inhibitors. About 90 people have received this treatment in Sweden so far, Gunilla Enblad, Chair of the national working group for CAR-T treatment, says to Life Science Sweden.

However, this therapy represents a treatment principle that is revolutionary in the true sense of the word, and in the future, it will probably be used as a treatment for diseases other than cancer. There are also hopes that the method can be used against several autoimmune diseases and also against viral infections such as sars-cov-2.

Photo: Adam Boman

SAMUEL LAGERCRANTZ
Editor-in-Chief

Contributers

Editor in chief
Samuel Lagercrantz
samuel.lagercrantz@nordiskemedier.se
+46 79 337 19 60

Reporter in Science
Karin Winter
karin.winter@nordiskemedier.se

Reporter in Science
Anders Göransson
anders.goransson@nordiskemedier.se

Advertising and events
Business Development Manager
Maria Eriksson
maria.eriksson@nordiskemedier.se
+46 72 015 53 66

About us

Life Science Sweden is a politically and organisationally independent publication owned by Nordiske Medier. We cover the medical treatments from idea and early science all the way through the society to the patient. This journey includes diagnostic, laboratory, regulatory and politics.

Need a subscription?
prenumeration@nordiskemedier.se

Address
Nordiske Medier
Sundbybergsvägen 1
171 73 Solna
+46 8 670 41 00

Translation: Scandinavian Office Solutions
Cover picture: Getty Images

Print and ads
Exakta Creative, exakta.se.
Material for ads:
annons.lifesciencesweden@nordiskemedier.se
Keep you updated everywhere!
Newsletter for free at lifesciencesweden.se.

Follow us on
LinkedIn and Twitter

SHIMADZU
Excellence in Science

i make the difference

The i-volution in HPLC analysis continues

The advanced i-Series of compact (U)HPLC systems has evolved to include Analytical Intelligence in the Prominence-i HPLC and Nexera-i UHPLC systems. The products combine high-speed analysis, simplified method transfer, automated sample pre-treatment, minimized environmental impact and easy maintenance with the flexibility of working remotely. They are ideally suited for applications in pharmaceutical, chemical and food industries.

Significantly improved analytical productivity through automation and remote control, resulting in increased efficiency and a reduced risk of human error

Analytical Intelligence integrates smart automation and utilizes advanced technology such as M2M and IOT to facilitate maintenance, simplify lab management and ensure consistently reliable results

Flexible software control by Shimadzu LabSolutions LC/GC, LC-MS or DB/CS for full FDA 21 CFR Part 11 compliance. Software packages from other vendors are also supported

www.shimadzu.eu/i-make-the-difference

ANALYTICAL INTELLIGENCE

"Spreading that sort of preconceived theories is very unfortunate when we still know so little about the root of the symptoms"

comments Jan Nilsson, member of the Royal Swedish Academy of Sciences' expert group on COVID-19, about claims that post-COVID is a "cultural disease". Read the full interview with Jan Nilsson on lifesciencesweden.se.

A Corona pandemic already in the 19th century? Researchers see parallels with the Russian flu

Photo: Getty Images

The Russian flu was an infection that was discovered in St. Petersburg in November 1889. In about four months, it spread around the world and killed about one million people. In Sweden, the first cases were reported in December 1889. So far, the Russian flu has been considered a flu pandemic, but according to researchers who have reviewed old descriptions of the disease, the symptoms are more similar to COVID-19 than the flu, reports Vetenskapsradion on Swedish P1. Another similarity is that the Russian flu affected the elderly to a much greater extent than young people. Among various influenza viruses, the Coronavirus HCov-OC43 has been identified as a possible cause of the Russian flu.

Photo: Novo Nordisk

Novo Nordisk is investing the considerable sum of DKK 17 billion in the extension and expansion of the company's production facilities in Kalundborg on Zealand, Denmark. The project is set for completion in 2027 and will employ an additional 400 people at the facilities in Kalundborg. The company estimates that 2,500 people will be hired externally to build the new facilities that will be used, among other things, to manufacture active substances for pharmaceuticals.

"Without health data, we will have no leading life science"

says **Markus Lingman**, Government Offices, Chief Physician and Strategist in Halland region, at a conference on life science organised by the Swedish government, the Västra Götaland region and Health Innovation West. Read more about the conference on Life Science Sweden's website.

"For companies developing medical technology, sustainability is definitely a factor that can provide competitive advantages"

says **Björn Ursing** in a column on lifesciencesweden.se.

Perspective



A cancer cell being eliminated by lymphocytes.

Photo: Getty Images

CAR-T therapies give continued hope:

"Almost half of the patients have become disease-free"

TEXT: ANDERS GÖRANSSON

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method.

"Almost half of them have become disease-free, at least of those treated with Yescarta, which are the ones I know best," says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.

UTILISING THE BODY'S immune system against cancer cells is a treatment strategy that has taken enormous strides in recent years, and CAR-T is one of the methods that has attracted the most attention.

So far, more than half of the treatments given in Sweden have taken place within the framework of various clinical studies, but in 2019, two CAR-T therapies also became commercially available after being recommended by the NT Council for use in the regions.

One of them is Yescarta, developed by Gilead Sciences' subsidiary Kite Pharma. It is administered to adult patients with two forms of lymph node cancer – diffuse large-cell B-cell lymphoma and primarily mediastinal large-cell B-cell lymphoma. According to Gunilla Enblad, Professor of oncology at the University Hospital in Uppsala and Chair of the national working group for CAR-T cell treatment, between 20 and 30 patients have received the treatment so far.

THE OTHER IS KYMRIAH, developed by Novartis, which was the first CAR-T therapy approved in the EU.

To date, about ten young patients with acute lymphocytic leukaemia, ALL, have been treated with Kymriah at the Karolinska and Sahlgrenska University Hospitals. These patients are very seriously ill and have not responded to other treatments or have had at least two relapses.

According to Peter Klint, Medical Director Novartis Oncology, the experience is positive.

"As always when introducing new drugs in oncology, it is a challenge that you often start by treating very ill patients, and naturally, there are safety aspects, but the treatment has proven effective. As a matter of fact, one can talk about a cure for some patients, which is outstanding and the reason why it attracts so much attention."

Since August 2018, Kymriah has been EU-approved for two indications in blood cancer: acute lymphocytic leukaemia in children and adolescents and diffuse large-cell B-cell lymphoma in adult patients. However, in Sweden, only the treatment for one of the indications, for children and young people, has been recommended by the NT Council so far.

Photo: Mikael Wallerstedt

Gunilla Enblad, chair of the national working group for CAR-T cell treatment.

CAR-T stands for "chimeric antigen receptor T-cell". CAR-T therapy was approved for the first time when Novartis' treatment Kymriah (tisagenlecleucel) was given the thumbs up by the US FDA in September 2017. The following year, the treatment was also approved within the EU. Since 2019, two CAR-T therapies have been available in Sweden. These are Kymriah and Yescarta, the latter of which was developed by Gilead Sciences' subsidiary Kite Pharma. There are a total of five CAR-T therapies approved in the EU.

Katia Eriksson Bragazzi and Peter Klint at Novartis Sweden.

Photo: Novartis

KATIA ERIKSSON BRAGAZZI, Country Manager at Novartis Oncology, regrets this.

"Real-world data from other countries shows that the treatment is effective and important for the adult patient group as well. We are in dialogue with the NT Council and TLV about developing our data for a re-examination," she says.

Novartis has several ongoing studies in which Kymriah is being tested for more indications in haematology, and according to Peter Klint, the data looks promising so far.

"Furthermore, we have a completely new generation CAR-T in the pipeline, which will hopefully provide an improved and more long-lasting effect, greater safety and which will also be easier to produce. So, we continue to invest heavily in CAR-T."

> Furthermore, we have a completely new generation CAR-T in the pipeline

Five of the university hospitals – Stockholm, Gothenburg, Lund, Uppsala and Linköping – are currently performing CAR-T treatments. They are extremely expensive, and the one-time treatment costs just over SEK 3 million. Currently they are only approved for third-line treatment of patients who have not responded to other therapies or who have had two relapses.

ACCORDING TO GUNILLA ENBLAD, it is difficult to answer whether enough patients are offered CAR-T treatment today.

"In the initial phase, I think there were some obstacles, but now I think patients in most cases get the treatment if their indications show that they are suitable for it," she says.

She predicts that the indications will expand in the future and that the treatment method will then be relevant for significantly more patients.

"I think CAR-T will grow as a treatment, and I believe what will happen first is that the therapy will be moved forward and given earlier in the second-line treatment. Several studies show that if you give the treatment at the first relapse and compare it with bone marrow transplantation, the results are better for the patients who receive CAR-T." ■

This is how CAR-T therapy works

The first step in the treatment is to purify T cells, which are a kind of immune cells, from the patient's own blood. The cells are then sent to a laboratory where a gene is added that causes them to express the receptors CAR, chimeric antigen receptors, to learn to recognise and kill cancer cells. The T cells are cultured for three to five weeks before being returned to the patient's body, where they start doing their job.

Swedish company Elicera develops CAR-T against solid tumours, which may be the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well.

"It is the largest field, and the potential is enormous," says the company's CEO Jamal El-Mosleh.

TEXT: ANDERS GÖRANSSON

Photo: Elicera Therapeutics



Dr. Di Yu and Professor Magnus Essand, researchers at Uppsala University and cofounders of Elicera Therapeutics.

ALTHOUGH THE METHOD has been described as a revolution in cancer care, today, there is only one Swedish company developing CAR-T treatments on a commercial basis.

Elicera Therapeutics has two CAR-T candidates under development. One, ELC301, is targeted at B-cell malignancies and the other – which is rarer – at certain types of solid tumours.

The latter candidate, called ELC-401, is primarily focused on glioblastoma, an aggressive form of brain tumour, but it can also be applied as a treatment for other solid tumours, such as colon cancer, pancreatic cancer and melanoma.

Those developing CAR-T therapies to fight solid tumours all face the same problem: a solid tumour has a highly immunosuppressive microenvironment, unlike blood cancer, which is easier to access.

Elicera's trump card is Itank, a proprietary technology platform. A process is initiated by placing a gene in the CAR-T cells, which fights the immunosuppressive microenvironment and makes it easier for the CAR-T cells to infiltrate the tumours.

"In addition to binding and attacking the tumour cells that carry the target that the CAR-T cells are targeting, we can also activate the patient's own killer T cells against

Photo: Elicera Therapeutics

Jamal El-Mosleh, CEO Elicera.

the entire set of targets. So, there will not only be an attack on one target but on all targets that are relevant to tumour cell attack," says Jamal El-Mosleh.

ACCORDING TO HIM, animal trials have shown that the platform is universally compatible with various CAR-T cell therapies and that it enhances their effect, regardless of which tumour type or target in the tumour the treatment is aimed at.

Currently, there are about a hundred companies in the world that develop CAR-T therapies, but at Elicera, they think they have found a way forward with huge potential in solid tumours through Itank.

"This is a fairly unique technology. We have identified another company working on something similar, a Japanese company. They have managed to generate eight different collaboration and licensing agreements with CAR-T cell developers. This highlights that this is a problem that many are facing, and which is difficult to solve, so this should be of great interest to other CAR-T developers as well."

The company is currently planning a clinical trial of ELC-301 in the treatment of B-cell malignancies, and last autumn, an agreement was signed with Biontech IMFS, which will be the contract manufacturer of the necessary retroviral vectors. The hope is that the study will be able to start in 2022.

In addition to its two CAR-T candidates, Elicera is also developing two oncolytic viruses. These viruses have been genetically modified to selectively enter cancer cells and replicate themselves to such an extent inside the cells that the cancer cells burst and die while the healthy cells remain untouched. ■

Photo: SDS Life Science

ANNA TÖRNER
Founder of
SDS Life Science.

Success requires bold decisions!

WE MAKE HUNDREDS of decisions every day, most of them so insignificant that we do not even perceive them as decisions. Some of the decisions are more important. We consciously weigh our options and usually make a relatively quick choice. From time to time, we make crucial decisions, which have far-reaching consequences and are difficult to reverse.

Sometimes, we push the crucial decisions before us and choose to solve the challenges by making less incremental decisions. The tricky thing is that if we duck for the crucial decisions, we will make them anyway, only indirectly. In the long run, a long list of more minor decisions of the 'bicycle parking decisions' type will also become crucial decisions, simply because we have missed the opportunity to make the difficult decisions proactively. We tend to think that things cannot go completely wrong if we avoid sticking our heads out and thinking for ourselves. At least, it will not be our fault.

> Doing things right is fine, but doing the right things as soon as possible is even better”

After all, our own initiatives are the first step towards a possible failure. However, not choosing will also become a choice. Sometimes we need to make bold choices linked to huge investments. Sometimes a brave decision is to dare stop a development project because the opportunity to succeed is non-existent.

DEVELOPING DRUGS MEANS being at the forefront of research, the exact same thing has not been done before, and there is no final conclusion showing us the right way forward. Whom of us has not encountered minor drug projects, often headed by the inventor themself, underfunded and without access to the necessary expertise. They are moving forward at a snail's pace during years of 'development', assisted by pocket money from Vinnova. You think that no damage has been done, we have not made any major mistakes, but that is not true.

A project that is moving so slowly in an industry under rapid development is actually going backwards. Time in the sense of 'lead over competitors' and 'patent time' are invaluable currencies in the toughest industry in the world. Doing things right is fine, but doing the right things as soon as possible is even better.

WE HAVE SEEN several Swedish companies succeeding with important development projects during the past year. Among others, Sedana Medical AB has secured European approval for its inhalation treatment Sedaconda®, Calliditas Therapeutics AB has received FDA approval for Tarpyo® for treating IgA nephropathy, and CombiGene has signed a very favourable agreement for its gene therapy with Spark International, a wholly owned subsidiary to Roche.

None of these achievements would have been possible without "gutsy" initiatives based on careful analysis of potential options. Other projects have failed at the finish line, and unfortunately, this is inevitable. In order to succeed, we must be willing to take the risk of failure.

So, what point am I trying to make? We, who work in life science, must be willing to look up and choose the compass direction. No matter how hard it is, we must be willing to make the crucial decisions. There is no guarantee of success, but chances of success are zero without brave decisions. ■

Stockholm aims at becoming one of the world's top life science regions

Photo: Region Stockholm/ Moderaterna

Irene Svenonius, Regional Chair for Finance in Stockholm, is convinced that Stockholm can reach a top 5 position in life science among the world's cities.

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world's top 5 regions in life science by 2025. One step of the way to achieve this is by hosting a world-leading congress in medtech.

TEXT: KARIN WINTER

STOCKHOLM HAS APPLIED to host the world congress in medtech 2028, IUPESM. Stockholm's Regional Chair for Finance, Irene Svenonius (M), believes that hosting the congress would be beneficial for Sweden's capital as it would be an opportunity for the region to learn from other world-leading players in medical research and treatment. Stockholm as the world's fifth foremost city in life science is a goal that is backed by several people in Stockholm whom Life Science Sweden has talked to. It is a goal that is shared by Irene Svenonius.

How will Stockholm get there?

"We must get the maximum benefit from all the investments in research infrastructure made by the region, the academies and private companies for a number of years. An acknowledgement of our regional strategy for life science is one of the most important measures we are working on right now so that it can be applied in the companies and ensure that our entire organisation pulls in the same direction to promote Stockholm's position."

According to Irene Svenonius, another important aspect for the region is the continued development and strengthening of collaborations between the universities in Stockholm to become even sharper as a research region.

Photo: Erika Aminoff, Blicka Studio

Ylva Williams, CEO of the Stockholm Science City Foundation, works to strengthen Stockholm's competitiveness in life science.

ONLY AMERICAN CITIES such as Boston and San Francisco are usually found in rankings over the strongest regions in life science. Is it even possible for Stockholm to reach the absolute top level?

Ylva Williams, CEO of the Stockholm Science City Foundation, which works to strengthen Stockholm's competitiveness in life science, believes so. Vision 2025 for Hagastaden was written in 2007, and now, about 16 years later, much has been realised.

"Vision 2025 communicated the wish for an institute similar to Scilifelab, and now we have it. It also communicated the wish for a new university hospital, which has also been realised. Presently, we have 130 companies in Hagastaden. I believe that we have realised most of the goals in the vision," she says. ■

Aspirations to host an international congress

The International Union for Physical and Engineering Science in Medicine organises the *World Congress for Medical Physics and Biomedical Engineering*, IUPESM. The next congress will take place in Singapore in June this year. The Swedish Society for Medical Engineering and the Swedish Association of Medical Physicists have applied to host the congress in 2028. The application is backed by the Stockholm Region, Karolinska Institutet, KTH, MedTechLabs and many others as a means to become one of the world's leading cities in life science.

Photo: Tove Smeds

PETTER HARTMAN
CEO at Medicon Village Innovation

Promote doing the right thing when recruiting international expertise!

IN RECENT DECADES, the globalisation trend has dramatically increased the exchange of capital, labour, goods and services, resulting in an intensified battle for talent, which creates opportunities for Sweden, provided that we make it easy to do the right thing.

Sweden's position as a leading research and innovation nation is dependent on foreign researchers and experts applying here. The demand for international labour is high, not least in life science, and the risks of an impending shortage of skills have been laid out as one of the major challenges facing our competitiveness in the coming years. This is also emphasised in the Swedish national life science strategy, in which lifelong learning and international recruitment are highlighted as priority areas for action.

Despite the apparent broad political agreement that it should be attractive for highly educated people to apply to Sweden, the debate has primarily been about skills expulsions and tightening of the law on labour immigration. Testimonies of unscrupulous forces have made the issue of foreign labour a complex political balancing act for the parties in the Swedish Parliament (Riksdag), where austerity measures to prevent cheating and people being exploited by dishonest employers must be weighed against regulatory simplifications and incentives that make it easier to recruit and attract talent to Sweden.

SEVERAL EFFORTS HAVE been made to make Sweden an increasingly attractive destination for foreign experts in recent years. In 2021, for example, the R&D allowance was strengthened through a further reduction in employer contributions for people working in research and development. Furthermore, the expert tax period was recently extended from three to five years, and in December, the government followed up with a proposal for a new residence permit for "certain highly qualified persons".

These efforts are very welcome, but unfortunately, major challenges still need to be resolved. As the newly appointed CEO of Medicon Village Innovation in Lund, I meet companies on a daily basis that express their frustration with the bureaucratic jungle that characterises the processes of hiring international experts, as well as long processing times at, for example, the Swedish Migration Board.

SCANIAN COMPANIES ARE not alone in having this perception. As early as 2018, the problems were highlighted in a memo by Growth Analysis (Tillväxtanalys) entitled "The competition for international competence". In addition to the long processing times for extending work permits, the interviewed companies also pointed out other obstacles that must be overcome, such as difficulties for accompanying parties to find work, lack of places in international schools, and bottlenecks in the housing market.

> Sweden's position as a leading research and innovation nation is dependent on foreign researchers and experts applying here"

Access to foreign researchers and other key people is central to developing outstanding research and securing the competitiveness of Swedish life science. The message to the international world must be that it should be easy to come to Sweden to realise their career dreams, and it should be easy for our Swedish life science companies to do the right thing. This requires clear rules on labour immigration and shorter lead times in government administration and management. Solutions to the above issues should be in everyone's interest and should be urgently prioritised by the government in 2022. ■



In the new stem cell centre, Renew, the researchers will work with different tissue types from stem cells. Here is a 3D reconstruction of the small intestine based on so-called confocal microscopy.

Photo: Kim Bak Jensen/ University of Copenhagen

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and new stem cell therapies.

TEXT: KARIN WINTER

THE UNIVERSITY OF COPENHAGEN will host a new international stem cell research centre. The new centre, Renew, is a collaboration with the Murdoch Children's Research Institute in Australia and Leiden University Medical Centre in the Netherlands.

The aim is to deliver new stem cell-based treatments to patients with incurable diseases by supporting basic science and passing on important knowledge to clinics. This can be achieved through the combined expertise that exists among the researchers at the three departments, according to Kim Bak Jensen, Professor at the University of Copenhagen and Deputy Director of Renew in Copenhagen.

"NATURALLY, WE ARE excited about these opportunities, and we hope and believe that we will be able to bring cellular therapies closer to human patients and use them in vitro stem cell-based disease models to identify new therapeutic compounds and treatment strategies for incurable diseases," he says.

Kim Bak Jensen will lead the work together with Melissa Little, Professor at Murdoch Children's Research Institute in Australia, who will be the director of the centre's three departments and who will also be appointed as a professor at the University of Copenhagen.

Novo Nordisk Foundation is backing the investment and dedicating DKK 2.2 billion to the centre. ■

Photo: University of Copenhagen

Kim Bak Jensen is Deputy Director of the new research centre.

Nordic life science – We must bake a bigger cake!

AMBITIONS FOR SWEDISH life science are high, and Sweden also aspires to become a leading life science nation. This was made clear in the annual Swedish life science conference "Together for a leading life science nation", arranged by the Government Offices, the Västra Götaland region and Health Innovation West. The conference offered an extensive list of speakers who revealed an already strong collaboration between public authorities, the private sector, academia and, increasingly so, with patient organisations that also strengthen patients' perspectives.

Some of the focus topics were the increasing competitiveness, the possibilities of attracting international talent and investments and opening the doors, not only to increased national collaboration but also reaching out to the neighbouring Nordic countries. The four Nordic countries, Sweden, Denmark, Norway and Finland, all have national life science strategies, but Sweden is the only country that mentions Nordic collaboration in theirs. Hats off to Sweden for highlighting this crucial aspect!

WE TRULY HAVE something to build on in the Nordics. The Nordic countries top the global innovation list, valuable healthcare data is available, and the life science industry is well-established, especially in Sweden and Denmark. Our internationally highly ranked universities have a long history of academic excellence and public-private partnerships in life sciences. Furthermore, the Stockholm-Uppsala cluster and the Swedish-Danish cluster Medicon Valley are home to world-class research facilities, a vital mass of life science industry, including a viable ecosystem of start-up life science companies, as well as Science Parks and incubators.

Sweden and Denmark have also adopted ambitious national life science strategies, and in both countries, the life science sector has gained increased focus and status as essential for ensuring the health of our citizens and resuming economic growth.

During the COVID-19 pandemic, the importance of a strong life science industry was further emphasised. Interestingly, in 2020, we saw a boom in patents from both Sweden (19% increase from 2019) and Denmark (9% increase from 2019).

Sweden and Denmark, Stockholm-Uppsala and Medicon Valley can together convincingly position the Nordic region as one of the leading life science regions in Europe and thus attract further foreign investment and talent.

THIS YEAR, THE Medicon Valley Alliance celebrates its 25th anniversary and can celebrate the fruits of successful collaborations between the public sector, academia and business in southern Sweden and eastern Denmark. The strong Swedish-Danish collaboration across the Oresund with Medicon Valley Alliance's more than 300 members has contributed to the development of world-leading strong positions in research areas such as fertility, diabetes and the microbiome. Our philosophy is simple; Medicon Valley Alliance strives to make 1 + 1 = 3 by creating more vital mass and baking a bigger cake for the benefit of the entire Swedish and Danish life science ecosystem.

Therefore, we are delighted to find that the cross-border collaboration is mentioned in the Swedish life science strategy. We welcome further collaboration to make the cake bigger in order to strengthen Swedish life science with solid positions and synergies originating in Medicon Valley.

Medicon Valley Alliance wishes to contribute with our strengths; cross-border collaboration in life science, by which we can build on the message from the conference "Together for a leading life science nation" and ensure that the Swedish life science strategy remains a living document, nationally and internationally.

ANETTE STEENBERG,
CEO of Medicon Valley Alliance
ULF ANDERSSON,
CEO of Medeon and
Vice President of Medicon Valley Alliance

Photo: Getty Images

Lundbeck behind the first EU-approved intravenous migraine treatment

A preventive, intravenous treatment for migraines has been approved in the EU for the first time.

TEXT: ANDERS GÖRANSSON

THE EUROPEAN COMMISSION has decided to approve the drug Vyepti (eptinezumab) for the preventive treatment of migraines in adults who have at least four migraine attacks per month.

The announcement was expected, as the European Medicines Agency's Expert Committee on Medicinal Products for Human Use, CHMP, issued a favourable statement in November last year, recommending that the medicinal product be approved. The treatment has already been approved in the USA and several other countries, for example, Australia, Canada and Switzerland.

The approval is based on the results of two Phase III clinical trials, in which the treatment proved to reduce the number of days with migraines per month compared to placebo. The first study, Promise-1, evaluated the treatment in patients with episodic migraine (headache for 4-14 days per month). The second study, Promise-2, focused on chronic migraine (headache for 15-26 days per month). According to study results, efficacy compared to placebo was evident as early as the first day after infusion.

Vyepti is a humanised monoclonal antibody that blocks the effect of CGRP (calcitonin gene-related peptide), which is very common in sensory nerves and is linked to pain transmission.

The drug was developed by Lundbeck, who expects the drug to be launched in the first European countries in the coming months. ■



Photo: Colourbox

The route to vaccines for everyone: *“We did not just sit and wait”*

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.

TEXT: ANDERS GÖRANSSON

FROM RELATIVE ANONYMITY among the public to being a practically daily face on TV and device screens, carrying the hopes, doubts and anxiety of the entire Swedish people on his shoulders. It has been an intense time for Richard Bergström, Sweden’s vaccine coordinator.

When Life Science Sweden calls, he answers from his study at home in Zug, Switzerland. This was also where he was in mid-June 2020 when he received the call from the Government Offices. It’s 20 months ago now, but the situation has not calmed down yet.

Just a few hours before our conversation, the government and the Swedish Public Health Agency gave new information about the COVID-19 vaccine. The phone has been ringing throughout the morning.

“Now they want to know whether we have sufficient quantities and who has fixed it. The European Commission fixed it. We did not just sit and wait, so we have already signed the contract and bought the doses,” he says.

DURING THE END of autumn, Richard Bergström received an honorary award from Research!Sweden (Forska! Sverige) for having “shouldered the responsibility for the vaccine supply for Sweden in a crisis situation and tirelessly handled challenges along the way”. He shakes off the solemn words.

“Well, I’m just a single cog in the wheel. However, it is certainly an honour to receive this award, even if it should rather be awarded to the EU process, or to the EU itself.”

The reason for accepting the assignment as a national vaccine coordinator was partly due to a sense of duty, and partly because he was actually ready for it.

“Yea, even though I was busy with my consulting company here in Switzerland, I came from that specific industry and followed the scientific development very closely. I was convinced that we would get the vaccine one way or the other and that the process would be faster than many expected.”

HOWEVER, HE SAYS, the outcome of all the vaccine agreements was not a given thing. The situation was resolved when the European Commission stepped in, appointed a steering group and took over the process.

According to Richard Bergström, a little-noticed but crucial element in the EU’s vaccine hunt was when the steering group, at an early stage, decided to invest in the mRNA vaccine candidates from Pfizer/Biontech and Moderna alongside the virus vector vaccines from Astra Zeneca and Janssen.

Most EU countries were extremely hesitant at this stage, partly because the mRNA vaccines required storage in extreme cold and partly because the technology was completely new. No such drugs existed at the time.

Photo: Samuel Lagercrantz

Richard Bergström when speaking at Life Science Sweden's New Horizons in Biologics & Bioprocessing meeting 2020.

Received an honorary award from Forska!Sverige

Richard Bergström received an honorary award from Forska!Sverige on 1 December 2021. The award motivation reads:

"The award is given to Richard Bergström for having shouldered the responsibility for Sweden's vaccine supply in a crisis situation and tirelessly handled challenges along the way to ensure that the population would be able to protect themselves against COVID-19 as quickly as possible."

"The group found that the majority of countries did not want them. But it was our job to make sure we were fully covered. So, we made our decision and signed an agreement for 300 million doses of Pfizer/Biontech vaccine, even though only 7-8 countries were interested in it then," he says.

Today, we have sufficient quantities of vaccines – the only problem is that not everyone wants to receive them. What is your view on that?
"It´s getting more and more frustrating. Initially, I had the opinion that it should be voluntary, and I deeply respected the fact that people are cautious and a bit sceptical. But now, half a billion people have received the mRNA vaccines without problems, so what more reassurance do you want? It beats all the clinical trials that have ever been made!"

RICHARD BERGSTRÖM WAS a well-known profile in the pharmaceutical industry even before his assignment as the government's vaccine coordinator. He graduated in 1988, and at the age of 22, he became Sweden's youngest pharmacist. The Medical Products Agency immediately hired him, and after that, he worked for nine years at Roche and Novartis in Switzerland. Then he returned home to Sweden, and in 2002, he became CEO of the Pharmaceutical Industry Association, Lif.

"At that time, we were often in turbulence. We were criticised and made out to be the bad guys in the media. But we made a journey, the board, Lif's chairman Steinar Höeg and me. We soon took hold of the ethical regulations and put a stop to invitational travel and the like, which was common at the time. We managed to close that debate about the industry, and I'm proud of that."

AFTER NINE YEARS at Lif, he worked six years at its European counterpart EFPIA, after which he switched to consulting work in, among other things, drug safety. Until the Ministry of Social Affairs called. During the autumn, the assignment as the vaccine coordinator was extended until 30 June 2023.

What does the future hold after that? Can you see yourself in the pharmaceutical industry again?
"I do not know. I have always worked in the space between the public and the private sectors, and I have moved a little back and forth there, and I will continue to do so. There is still so much left to do, not least in market access. And there is a lot to reflect on about what happened in vaccine development. Shouldn't we develop new antibiotics as well in the same way?" ■

Photo: RegSmart Life Science

MARIE GÅRDMARK
CEO and Senior Consultant
at RegSmart Life Science.

Finally, it's time for a revision of EU pharma legislation

IT IS EXCITING times ahead for those interested in the future regulation of pharmaceuticals. It should be a priority for everyone and not only for regulatory nerds like myself. Much has happened since the last update of the EU legislation. New technology has led to an increase in the understanding of disease mechanisms and the design of "targeted therapies" that more specifically address medical needs – precision medicine. Concerning this, the legislative initiative to stimulate the development of new products for rare diseases, launched 20 years ago, has been very successful. However, research is developing with, for example, an increasing number of gene and cell therapies under development offering curative treatment that not only put pressure on the regulatory requirements but may also require a new business model.

One of the focus areas in the EU pharma strategy is fostering innovation, specifically in areas of unmet medical needs. The EU system also needs to adapt to new scientific and technological developments through tailored incentives for innovation support. How the innovation strategy will be implemented in the legislation without lowering the requirement for approval remains to be seen. It is likely that the basic approval requirement to show positive absolute benefit-risk will remain.

GIVEN THAT THE Commission highlights the technological development and that the new EU regulation for medical devices was recently implemented, it will be interesting to see if any new initiatives are taken to simplify medicinal products with a device component. These include clarifying roles and responsibilities, streamlining requirements and procedures, and building up the necessary regulatory expertise and collaborations. It seems likely that the technological development will lead to the convergence of the pharma and medical device regulation.

Today, the EU regulatory system is based on collaboration between national medicines agencies and the EMA. The Commission will explore the need to recognise more formally the role of the network of national medicines agencies and its operational structure in the regulatory system, which may alter the "power balance" between the EMA and national medicine agencies, potentially towards a stronger EMA. In the long-term, the collaboration is essential, not least to ensure the best regulatory competencies throughout the EU.

NOW A TREMENDOUS amount of work starts to draft new legislation text, and the regulatory medicine agencies in the EU will have busy years ahead with a vast number of expert groups to deliver the exact wording, and I can assure you that every single word is important and discussed in detail. One sincerely hopes that knowledge and experience from industry will be carefully addressed in this process.

The intention of the new legislation from the EU Commission's side is very promising, but it must be revised in a way not to create further complicated and inefficient processes that will add complexity to the EU and drive companies to prioritise other regions for approval and marketing of their innovations. So, let's hope that the Commission successfully harmonises the regulatory approval times with those in other parts of the world. It is encouraging to read that "reducing bureaucracy" is one goal of the new legislation, but so far, this has not been one of the hallmarks of the EU system.

A challenge for the EU Commission is to deliver a new framework that will also take care of another "pillar" of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe. Maybe this will be the hardest to achieve. ■



Photo: Getty Images

Study: An objective diagnosis of constant tinnitus may be possible

A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tinnitus, which was demonstrated in a study made by researchers at the Karolinska Institute.

TEXT: ANDERS GÖRANSSON

TINNITUS, SOMETIMES described as phantom sounds only perceived by the subject, affects every fifth Swede in some form. Today, the severity of the condition is measured only by self-assessment via questionnaires.

A new study published in the Journal of Clinical Investigation now shows that a method called brainstem audiometry can become a tool for making an objective diagnosis.

"It is much needed, both for doctors to verify the patient´s statements and give recognition to affected patients. Furthermore, drug developers need an objective way to quantify the result of the treatment," says Christopher Cederroth, a researcher at the Department of Physiology and Pharmacology at the Karolinska Institute and one of the study authors.



Photo: Annika af Klercker

Christopher Cederroth is a researcher at the Department of Physiology and Pharmacology at the Karolinska Institute and one of the authors of the new study on the diagnosis of tinnitus.

BRAIN STEM AUDIOMETRY measures brain activity in response to a specific sequence of sound stimuli. Today, the method is used, among other things, to find tumours in the cerebral cortex and to detect hearing loss in young children, but it appears to be sensitive enough to diagnose tinnitus as well.

In the study from the Karolinska Institute, the researchers measured 405 people with brainstem audiometry, of which 228 with tinnitus and 177 without.

"The result shows a measurable difference in the neural response in those with constant tinnitus, and we believe that it may become a future biomarker. However, we need more studies to verify that and measure treatment benefits," says Christopher R. Cederroth.

THE SAME STUDY also followed 20,000 people with no or varying degrees of tinnitus.

"The result was, among other things, that those with frequent tinnitus are at higher risk of contracting it constantly. This suggests that when tinnitus becomes constant, it is likely that the neural activity in the brainstem has been permanently altered."

The study was conducted in collaboration with the Karolinska University Hospital, Stockholm University, the University of Bergen and the company Decibel Therapeutics. ■

Anette Steenberg on her vision for Swedish-Danish life science

Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to ask about her visions and the challenges of merging the worlds of Swedish and Danish life science.

TEXT: KARIN WINTER

What is your vision for Medicon Valley Alliance?
"My aim is to put Medicon Valley on the world map as one of the most competitive regions in life science and at the top in Europe. To achieve this, I must prove and convince both the national Swedish and Danish governments that by strengthening our collaborations and nodes in MWA, we will create a scenario where one plus one becomes three. This will not only benefit the life science cluster in MVA, but it will also strengthen Sweden and Denmark as two leading life science nations."

Photo: Medicon Valley Alliance

What are the challenges of merging Swedish and Danish life science?
"In my opinion, the biggest challenge is to make the two national governments recognise that we have a win-win-win situation here, provided that we strengthen and promote our common life science cluster internationally. There are differences in the structure and framework for the life science cluster on the Swedish and Danish sides. However, I do not see them as challenges, but rather complementary fields that make the cluster even stronger."

What will be your contribution to MVA?
"As a former diplomat and most recently as head of attracting foreign direct investment, I have solid experience navigating the public-private sphere by promoting a company, a sector, a region or countries' nodes to attract foreign direct investors and talent. Moreover, I have worked with company growth and internationalisation, especially in regulated sectors in which strong cooperation between public, private and academic organisations is either required or advantageous, which is especially important in the life science sector."

Former CEO Petter Hartman is Swedish, and you are Danish. Will that influence your position in any way?
"My predecessor successfully engaged Swedish companies and researchers in MVA. I will work hard to maintain and build on that. However, MVA is still well established in Sweden as about half of the members are Swedish. And naturally, since I am not Swedish, I will make an extra effort to get to know the Swedish key opinion leaders in life science." ■

Anette Steenberg

Lives: Bagsværd, 13 km north of Copenhagen City Hall.
Age: 53.
Family: A daughter, 19-years-old and a son, 16-years-old.
Interests: Current issues, travelling, playing golf, diving, good wine and spending time with family.
Last book read: Hillary Rodham Clinton's book *State of Terror*.
Pet: Ally, a black Labrador, named after the lawyer in the TV series Ally McBeal.

Photo: STUNS Life science

BJÖRN ARVIDSSON
Managing Director,
STUNS Life science

We need to change perspective

If you say "life science" to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network will generate as many versions as the people you ask. Most likely, we will miss many opportunities with our lack of communication.

LIFE SCIENCE IS goods and services that directly or indirectly have to do with treating patients or citizens' wellbeing. Sometimes I say that life science is the ability to understand and enhance the standard of life. However, both of these explanations are very abstract for the uninitiated.

At the same time, life science, just like other sectors, is dependent on recruiting skills outside its industry, mostly as a result of the digital transformation. We also know that investors often specify themselves within life science, where we would like to see that those who do not invest today would do so as well. But of course, they then need to understand what they are investing in. And if we are to be able to benefit from interdisciplinary collaborations, our potential partners must know how we can benefit from each other. Thus, our communication is crucial in many ways.

WE UNDERSTAND MEDICAL TECHNOLOGY, pharmaceutical drugs, and diagnostics, but we see an apparent widening towards, among other things, materials science and food tech. At the same time, the increase in access to data means that e-health, digital health, and health tech areas also place themselves within life science. Furthermore, we have large manufacturing industrial companies as well as smaller, more lab-close developers. Additionally, we have both entrepreneurship and care. And soon, the public sector will have even greater responsibility for health in general, increasing the number of players who profess life science.

So, what are we doing?

IT'S EASIER TO SAY that you work with healthcare or medicines than life science. Maybe we are doing ourselves a disservice by including too much within the framework of the same expression. A desire to simplify that only makes it more complicated. For the individual player, it is enough to say what they do. Still, for all those who work for the system, for the regional attractiveness, to position Sweden as a strong life science nation, to attract talent, investment, and establishment, the clarity of the communication becomes even more critical.

And in competition with the rest of the world and other sectors with the same goal, we need to sharpen our approach.

The conclusion may be that if what we strive for is agnostic to our sector or region, then we should stop trying to describe our industry and instead talk about the societal challenges we want to solve. ■

LIFE SCIENCE SWEDEN

proudly presents...

Lab & Diagnostics OF THE FUTURE

April 7th 2022 • Swedish LabDays • Älvsjö

Lab & Diagnostics of the Future – the place to promote tomorrow's diagnostics

Among the speakers:

Moderator:
Giulia Gaudenzi
Researcher, SciLifeLab

Daniel Sund & Peter Tønning
BSc. Molecular biology, MSc. Environmental chemistry/MSc in physics and PhD in Photonics
Milmedtek AB & UV Medico

Disinfect any room or process – with people in it

Ray Legrand
Head of Lab Nordic
Tietoevry

Laboratory Diagnostics – An industry in transformation

Niklas Arnberg
Professor of Virology
Umeå University

It's some kind of virus

All delegates will have the opportunity to book 1-2-1 meetings through our partnering system that will open up two weeks prior to the event.
To participate as a delegate is free of charge. The event will be covered by the media.

labdiagnosics.eu

Organizer

LIFE SCIENCE SWEDEN

Partners

tieto EVRY

LAB360°

MMT MILMEDTEK AB

uvmedico

GIULIA GAUDENZI
is a researcher at
Scilifelab/KTH and
Karolinska Institutet

Innovation for good

A FEW YEARS ago, I visited the Science Gallery in Dublin, a dynamic science and art space, in the middle of the Trinity College university campus. The exhibition featured a curious piece called "The NeoNurture", an infant incubator for low-income hospitals. A MIT inventor designed the incubator to be made with local material recycled from old cars.

What I have not yet mentioned is that the exhibition's theme was "failure". The NeoNurture was a total failure, not because it did not work but because nobody wanted to use it.

The design prototype achieved worldwide recognition. It was even listed number one in Time Magazine as "Best Inventions of the Year", yet hospitals did not want the technology, although effective, made frugally of recycled car parts. The outcome of this was obvious, in low- and high-resource settings, likewise, medical devices need to "look" like a trustworthy medical device. As a researcher in global health diagnostics working among an interdisciplinary team of engineers, doctors and closely with end-users, I realised more and more that it is not enough to design a good product, it is necessary to design outcomes.

Although we have come a long way in understanding this process, so many brilliant prototypes still never create any impact. Yet, the challenges are not disappearing. By 2030 there will be 2 billion young people in the world, and many of those people will not be able to fulfill their potential, inheriting many challenges from the past, aggravated by the climate crisis and declining mental health. An inclusive, scalable, and sustainable innovation process is crucial for tackling such challenges.

UNICEF HAS RECENTLY established a global centre for innovation in Stockholm with the mission to be a trendsetter of innovation for equitable social impact for every child today, and generations to come. This new business model aims to align with global champions, such as Sweden, in a shared commitment to connect local to global innovation ecosystems for collective design, delivery, and investment. At the heart is working with young people around the world with both innovation needs and impactful local innovation solutions to be spread globally.

IN PARALLEL, THE International Vaccine Institute (IVI), an organisation with the mission to innovate, discover and develop affordable new vaccines for global health, has also established a regional office in Stockholm.

Such a landscape is extremely promising and exciting. However, stories of failures like The NeoNurture should be retold sometimes as a wake-up call that good frugal innovation is extremely context sensitive, and that blending local and context knowledge with cutting edge science and technology is key to producing impact and outcomes. In life science we need social innovation as much as product innovation; we need to involve the end-users and incorporate elements from implementation science to make ensure the innovation does not get lost in the "know-do gap"- the gap between what we know and what we do and implement.

Finally, I challenge the innovator landscape to take another mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences.

I wish to warmly thank Patty Alleman (UNICEF) and Stefan Swartling Peterson (Karolinska Institutet), from which our pleasant discussion inspired this piece. Views are my own. ■

On April 7th Giulia Gaudenzi will moderate Life Science Sweden's Lab & Diagnostics of the Future event at Swedish Labdays in Älvsjö, Stockholm. Read more at labdiagnostics.eu

Zelmic broadens operations creating a CDMO for topical products

Zelmic develops topical (topically applied) drugs handling small molecules, peptides, and proteins. Now they are taking the step and building a GMP plant to produce oral liquid and topical products for clinical studies.

– Our knowledge of topical products is unique. The three key parameters to be studied are formulation stability, drug release from the formulation, and drug permeation characteristics. We can run in vitro permeation tests on e.g., skin, nails, and mucous membranes. We feel confident in minimizing risk factors, project costs, and optimizing the best effect. By also offering to manufacture clinical material, we make it even easier for our customers to reach the clinical phase, says David Sagna, CEO of Zelmic.

The office and laboratory with the in-house research and development capacity around topical drugs are in Lund, Sweden. Previously, they worked up to and including the preclinical phases and manufactured for studies run according to GLP, Good Laboratory Practice.

Thereafter, customers have moved manufacturing to contract manufacturers under GMP, Good Manufacturing Practice.

To shorten the lead times and complications of manufacturing for clinical trials, Zelmic is now building its GMP plant.

– We will thus become more of a One-Stop-Shop, a CDMO that can offer both development and manufacturing, says David Sagna.

The idea is that Zelmic will help its customers with a more significant part of the development process by increasing the range of its services.

David Sagna, CEO fo Zelmic.

– We see that more and more customers are looking for an all-in-one solution. They want development and manufacturing to occur in the same place to reduce costs and lead times to enter the clinical phase. It is essential to get an experienced and skilled development partner who knows the development part. We can help them reach the clinical phase, faster, easier and safer, he says.

Work on the new GMP plant is in full swing, and it will be completed and operational this year. It is expected to have a capacity to produce on a small scale up to 8 kg per batch.

– Our hope is that in addition to development assignments, we will be able to take in pure manufacturing assignments, i.e. also manufacture for companies where we have not taken care of the development work, he says.

Zelmic also collaborates with other local companies to take the product further for commercial manufacturing and manufacturing for larger clinical studies.

– It feels like a natural step for us. We have gradually expanded the business. During 2019 we worked hard to improve the quality and implement GMP for the analytical lab and in vitro release laboratory. We can now perform in vitro release studies according to the new draft EMA guidance for topical products. We have brought in skilled staff and built a fantastic team of formulators, analysts, and QA with the skills needed to handle GMP manufacturing, scaling up, and this type of development assignment, concludes David Sagna.

FACTS

Zelmic is a contract development organization initially founded in 2002. It has developed several topical drugs and patented technologies for its customers. In 2015, Zelmic founded the listed company Pharmiva AB. The company offers services in topical formulation development for small molecules, peptides, and proteins. The analytical capacity is R&D, GMP analysis, validation, and stability studies according to ICH can be performed. Zelmic can perform in vitro performance testing with in-vitro release testing (IVRT), In-vitro permeation testing (IVPT) with skin, nail, and mucous membrane according to new draft EMA guidance.
Zelmic is now building a GMP facility for clinical manufacture.
Read more at: **www.zelmic.se**
https://www.linkedin.com/company/zelmic-ab

Medivir's new CEO: "Returning to oncology is like coming home"

Since the end of January Jens Lindberg has been the CEO of the cancer research company Medivir, which was founded in 1988 as a spin-off from Astra Zeneca.

TEXT: KARIN WINTER

Photo: Medivir

How was the first day at your new job?
"It was like every first day at a new job. I went to work with great confidence, but as always, you feel just a little incompetent on the first day. You ask a lot of questions and so on. To question your own competence is a rather peculiar feeling."

What is your vision for the company?
"Medivir's vision was one of the reasons why I chose to take on the role of CEO – to transform Medivir into a specialist company in the field of oncology. Naturally, my driving force is linked to the company's driving force – to push our self-developed drug candidate, MIV-818, from the clinical phase to market approval as quickly and safely as possible. MIV-818 has the potential to become the first liver-targeted, oral drug for patients with primary liver cancer – a group of patients with a great need for improved treatments. Pushing this forward and taking it over the finish line will be very exciting."

Did you feel absolutely sure when accepting the CEO position?
"Yes, I did. First and foremost, I look forward to leading and accelerating the transformation journey that Medivir has begun, which is very stimulating, and also, getting back to oncology – it's like coming home. There is an enormous potential in liver cancer, which is a neglected area. I also had the chance to try my hand at an interim stock exchange CEO role at Sedana Medical, and I feel ready for the CEO role."

How does it feel after the first days?
"In addition to being able to return to oncology, I have a good feeling about the team and the board, who are extremely experienced and competent. Magnus Christensen has pushed on as interim CEO, so it's not like jumping on a bus that has been driven to the side and parked. They have done an outstanding job in 2021, and I am grateful that Magnus has pushed on in his dual roles in the meantime." ■

Jens Lindberg

Age: 50.

Family: Wife Gunilla and 3 sons aged 19, 17 and 13.

Lives: Danderyd outside Stockholm.

Career in brief: 25 years at Astra Zeneca in various roles with a mainly commercial focus. In addition, 2 years in medical technology at Sedana Medical, with commercial responsibility and as interim CEO for a period.

Interests: Cross-country skiing during the winter with the Vasaloppet as the big goal and boating with the family's motorboat during the summer.

Last book read: *The Five Dysfunctions of a Team* by Patrick Lencioni. "A book I have read several times and love to return to. One of the cornerstones of the book is how to build trust and security in the team to make it as well-functioning and committed as possible".

Subcutaneous absorption about to be described with mathematical models by Pharmetheus

Dr Marylore Chenel, Project Lead, and Assoc. Prof. Erik Sjögren, Subject Matter Expert.

Can we predict in silico what happens after a subcutaneous injection? Pharmetheus' scientists are extending their pharmacological modeling activities to this route of administration.

Vaccines are just one example of how the subcutaneous route of administration can provide a more convenient delivery of therapeutic proteins compared to intravenous injections. However, as observed for the intravenous route, when a drug is injected subcutaneously, it can trigger the generation of anti-drug antibodies that bind to the therapeutic proteins and thus reduce the efficacy of the drug.

This risk of triggering this immune reaction can be mitigated, to a certain degree, by selecting less immunogenic compounds and using bioengineering techniques specifically aimed at removing or hiding the immunogenic parts of the protein. Nevertheless, additional factors, such as the localization of the drug in a tissue and aspects related to drug formulations, still represent challenges for this specific route of administration.

"Currently, we can simulate how much drug the patients are exposed to after different oral doses. We already use these simulations to help our clients select the right dose for the drug they are developing. Similarly, being able to predict how therapeutic proteins are going to be absorbed and which immunogenicity to expect after subcutaneous administration are going to be key for both drug developers and patients." notes Marylore Chenel, Principal Consultant and Team Leader at Pharmetheus.

The scientists aim at combining the aspects and functionalities of "quantitative system pharmacology models" (traditionally used to characterize biological systems, disease processes, and drug pharmacology) and of "physiologically-based biopharmaceutics models". The latter models describe the behavior of a drug in the organism, based not only on the drug characteristics and its delivery system, such as physical attributes and administration route, but also the physiological characteristics of the individuals.

These methodologies are already successfully used to optimize chances of clinical success in drug development. Erik Sjögren, Senior Consultant at Pharmetheus, explains "In this case, we will integrate the mechanisms of drug absorption and of immune response toward therapeutic proteins administered subcutaneously, including relevant factors related to drug delivery."

FACTS

Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug research, development, and life-cycle decisions. This project is part of its engagement in optimizing chances of clinical success and facilitating risk mitigation in the development of drugs intended for subcutaneous administration. It is being co-financed together with Sweden's innovation agency, Vinnova, and further invigorates the existing commitment in the research forum SweDeliver.

Pharmetheus

How to network best via LinkedIn – "Help others find you"

You have decided to move on in your career. And then what? Tina Persson, career coach and author of "The PhD Career Coaching Guide", gives advice on using the LinkedIn business network.

TEXT: KARIN WINTER

TINA PERSSON.

Photo: Passage2Pro

The basic and most important thing to be successful on LinkedIn is to build networks, and according to Tina Persson, a good guide is to have more than 500 connections.

"You do not have to know people to connect but you need to think strategically – connect with those who have large networks. There are probably people who will accept your contact request. You should also not be afraid to contact people who are high up in the hierarchy, such as CEOs, who understand the value of networking."

To connect – send a message. But remember to be brief.

"Do not write your CV. Initially, it is not about applying for a job. You are often too eager at first. You just want to expand your network – you do not need an agenda. This is not about branding, but about people knowing who you are."

According to Tina Persson, an example of what you can write in a message is: "I want to expand my network in life science. I hope you want to connect with me. Wishing you a nice weekend, best regards, xxx."

To succeed in getting a job via LinkedIn, you need to know what you want, what driving forces you have, in what field you want to work and based on that, find the right keywords.

"In many industries, "buzz language" is used. The crucial thing is that you find the right words so that recruiters can find you. Help others find you." ■

Tina Persson's tips for LinkedIn

1. Build a number of connections and expand your network. You need 500 plus connections. Remember that you do not need to know people to connect.
2. Join groups in the field you would like to work within in the future. You can always leave groups if they do not suit you.
3. Snoop around on profiles and careers and learn from what others are doing. You can get inspiration from others. Find out where your friends and colleagues are going. Check out role models in the industry you want to be a part of.

Improved protein purification with innovative product

A new innovative product, WorkBeadsTM 40 TREN, has been developed by Swedish biotech company Bio-Works Sweden AB with the purpose of enhancing the purification process of biological pharmaceuticals.

Lone Carlbom

”It is a new way of purifying antibodies which leads to a more cost-effective process for our customers”, says Lone Carlbom, the company´s Head of Product Management.

Bio-Works, an Uppsala-based company, was founded in 2006 by four leading experts in protein purification. It has been growing rapidly and now has about 40 employees, with direct sales in Europe and USA.

The company is specialized in agarose-based resins for purification of biomolecules – including monoclonal antibodies, proteins, peptides, oligos, viruses and vaccines – for the pharma industry.

The new product, WorkBeads 40 TREN, is a salt tolerant, ion exchange resin working at what Lone Carlbom calls ”elevated ionic strength”. The unique composition of porous beads with tight bead- and poresize distribution leads to outstanding purity, high binding capacity and high flow rates.

”We use this product in a little different way compared to traditional purification of antibodies. By putting WorkBeads 40 TREN in front of your expensive affinity resins, you will protect it from impurities, and it will last longer and produce better results. The entire process will be more cost-effective.”

WorkBeads 40 TREN is now being tested by several customers in the market, and interest for the product is growing.

”We are very proud of this product which we think could change best practice in processes that use expensive affinity resins”, says Lone Carlbom.

Moberg Pharma's founder takes over Industrifonden

Peter Wolpert succeeds **David Sonneke** as the new CEO of Industrifonden. Peter Wolpert is the founder of Moberg Pharma and has worked as an advisor to A3P Medical and Oncozenge.

Industrifonden invests in the early stages of growth companies in deep tech, life science and innovative business models. The fund was established in 1979 by the Swedish government as an instrument to stimulate innovation-based growth. ■

PETER WOLPERT.

Elekta grabs the CFO from Recipharm

Elekta has appointed **Tobias Hägglöv** as their new CFO, succeeding **Johan Adebäck**, who will move on to another position in the company. Tobias Hägglöv was previously the CFO at Recipharm and has also held management roles at Leax, Electrolux, SAS and Accenture. He holds a master's degree in Industrial Economics and Business Administration, as well as a master's degree in Business Administration from Stockholm University. ■

TOBIAS HÄGGLÖV.

Pharmiva strengthens its organisation

The femtech company Pharmiva has appointed **Karoline Akerjordet** as their new Deputy CEO. She was previously the COO at the company, and she has held leading positions at Novo Nordisk and Particle Measuring System. In addition to Karolina Akerjordert, Pharmiva's organisation has been strengthened with **Andrea Mildner** as the new Head of Marketing and Sales. ■

KAROLINE AKERJORDET.

Apoteksgruppen appoints a new CEO

Erik Sjögren has taken over as the CEO at Apoteksgruppen. He succeeds Tomas Kibildis, who chose to leave the post to lead the group's Eurovaistin pharmacy chain in Lithuania. Erik Sjögren has worked for Apoteksgruppen since June 2019, including building up chain operations during the time when the company was a pure franchise chain. When he stepped up as CEO in January, he also took a seat on Euroapotheca's board. ■

ERIK SJÖGREN.

Maria Lundberg has been appointed the new CEO of SDS Life Science

The consulting company SDS Life Science has appointed **Maria Lundberg** as their new CEO. For the past 21 years, she worked at Recipharm, where, among other things, she was responsible for global product development. She holds a chemical engineering degree from Lund University. **Jens Hansson** has been CEO of the company since the spring of 2021, and he will remain at Group level.
SDS Life Science has also appointed **Maria Fernström** Head of the clinical project management team. Most recently, she worked at the Karolinska Trial Alliance, where she was a group leader and unit leader focusing on academic researcher-initiated studies. ■

MARIA LUNDBERG.



MARIA FERNSTRÖM.

Covid-19 behind an accelerated move towards digital solutions for clinical diagnostics

Clinical diagnostics, a sector already seeing an annual 6% increase in blood sampling in Sweden, was put under tremendous pressure as the pandemic evolved.



"The immense increase in laboratory testing due to Covid-19 has put the clinical diagnostic sector in the spotlight", says Ray Legrand, head of Laboratory at Tietoevry, a leading supplier of integrated solutions for healthcare providers in the Nordics. "With Covid-19 everything exploded. The changes are huge and we will probably see a completely new landscape around clinical diagnostics and health care in general, once the dust settles. Up to now, developments have occurred progressively but what we are into now is more of a leap. The attention also means more investments and willingness to try new technologies which make this a very exciting area to work in".

The new technologies include cloud-based solutions for collecting and aggregating data and a lot more artificial intelligence (AI) for the diagnoses. Some of the obstacles today are due to legislation concerning safety. But most of the cloud companies use a big portion of their budgets for data security and can meet demands concerning safety and GDPR on a level which is as good, or probably better, as the current local and more traditional storage solutions. The possibility to gather the exponentially increasing amount of data into one place will minimize the fragmentation that the more conservative systems are suffering from. This will give access to a patient´s whole health history resulting in a more accurate diagnosis.

A successful example is The Hospital District of Helsinki and Uusimaa where a newly available HUS-DataLake, developed in collaboration with Tietoevry, has recently been implemented. The solution enables the analysis of huge datasets resulting in higher-quality healthcare and more cost-effective operations.

Roughly 80% of a physician's diagnoses are based on blood analyses which also make sampling procedures very critical, both from a speed and quality aspect. Tietoevry products are central in providing the IT and workflow support needed to produce quality patient laboratory results. "By evaluating the workflow at a pathology department in a Swedish hospital a team from us, in collaboration with an expert staff, were able to reduce the lead time from sample to diagnosis by several days. For us, it's very easy, and incredibly rewarding, to connect the dots from building solutions to saving lives", Legrand conclusively adds.

Ray LeGrand, with a previous background from working in the health care sector, became interested in IT in the early on, when he realized that the lack of infrastructure and IT support often couldn't keep pace with rapid development of new technology.

His laboratory experiences have helped him greatly in understanding the complex and highly integrated sector that health care represents. This is also how he would explain Tietoevry's main asset, having a good mix of people with different backgrounds and skills along with the passion to make a difference.

Boule appoints a new CFO

Annette Colin has been appointed the CFO at Boule Diagnostics. She came from a similar position at Biotage and previously, she held senior positions at, among others, Annexin, Pharmaceuticals, Observe Medical and Stille. Annette succeeds **Christina Rubenhag**, who will be the new CFO at Addlife. Annette Colin will take office on 1 April. ■


Photo: Boule Diagnostics

ANNETTE COLIN.

Capitainer is recruiting an expert for a venture in the United States

Donald Chace will represent Capitainer in North America when the Swedish medical technology company invests in the American market. He has published about a hundred peer-reviewed articles and has lectured in neonatology, clinical chemistry and screening of newborns. He has also previously developed a metabolic screening test for newborns based on dried blood from, among other things, PKU tests. ■


Photo: Capitainer

DONALD CHACE.

Dignitana appoints a CEO from Cellavision

Magnus Blixt has been appointed the new CEO of Dignitana. Most recently, he held the position as CFO at Cellavision. Magnus holds an MBA from Lund University, and previously, he held several positions within the SKF Group, including in the USA. He is succeeding the current CEO **William Cronin**, who will be the company's senior advisor and vice chairman. Magnus Blixt will take office at the Annual General Meeting on 25 May. ■


Photo: Dignitana

MAGNUS BLIXT.

Consulting company recruit from Sobi

Charlotta Hjerpe will be head of Key2Compliance's new business area Pharma QA, which is established to offer customers in the pharma sector services in quality assurance and quality management. Previously, she conducted academy research and held several different positions in the pharmaceutical industry, including project manager, operations manager and quality manager. Most recently, she worked at Sobi, where she has been since 2019. Before that, she was at Vironova. ■


Photo: Key2Compliance

CHARLOTTA HJERPE.

The Heart Lung Foundation's research council appoints a new Chairman

John Pernow, Professor at the Karolinska Institute, has been appointed the new Chairman of the Swedish Heart Lung Foundation's research council. He will lead the work of assessing and recommending which research projects will be awarded grants. John Pernow succeeds **Jan Nilsson**, Professor at Lund University. ■


Photo: Karolinska Institutet

JOHN PERNOW.

Naturvetarna gets a Chairman from the Swedish Research Council

Chemist and microbiologist **Patriq Fagerstedt** has been elected Chairman at Naturvetarna. Most recently, he came from a position as research secretary at the Swedish Research Council. Previously, he worked as a researcher at the Karolinska Institute and worked with drug development at Astra Zeneca. He was on the Board of Naturvetarna for nine years and was Chairman of the Saco association at the Karolinska Institute. ■


Photo: Naturvetarna

PATRIQ FAGERSTEDT.

2022

APRIL 7th
Lab & Diagnostics of the Future
Swedish LabDays, Stockholm
labdiagnostics.eu

Lab& Diagnostics OF THE FUTURE

MAY 16th
Life Science Sweden
No 2.2022 is published

SEPTEMBER 6th
New Updates in Drug Formulation and Bioavailability
MVA, Copenhagen
formulationsbioavailability.com

New Updates in Drug Formulation & Bioavailability

SEPTEMBER 7th
The Future of Swedish & Danish Life Science
Medicon Village, Lund
swedishdanishlifescience.se

The future of SWEDISH & DANISH Life Science

SEPTEMBER 15th
Life Science Sweden
No 3.2022 is published

NOVEMBER 8th
Bioscience – Research & Diagnostics through Innovative Technologies
Life City, Hagastaden, Solna
bioscienceevent.com

Bioscience

NOVEMBER 30th
Life Science Sweden
No 4.2022 is published

DECEMBER 1st
Pharma Outsourcing – Find the right partner
Stockholm Waterfront Congress Centre
www.pharmaoutsourcing.eu

Pharma Outsourcing Find the right partner

DECEMBER 15th
New Horizons in Biologics & Bioprocessing,
Stockholm Waterfront Congress Centre
www.bioprocessing.se

new horizons in biologics & bioprocessing

Photo: Anders Tidén/Medicon Village

Søren Bregenholt, CEO of Alligator Bioscience, was one of the speakers at the 2021 edition of The Future of Swedish & Danish Life Science. Here on stage with the moderator Sarah Lidé.

HIGH-PERFORMANCE LABORATORY MEASUREMENT INSTRUMENTS

Anton Paar

QUALITY SINCE 1922

WORLDWIDE SERVICE AND SUPPORT NETWORK

WITH 33 SUBSIDIARIES AND 50 DISTRIBUTION PARTNERS

ANTON PAAR NORDIC

PROVIDES SALES, APPLICATION SUPPORT AND SERVICE TO USERS ACROSS SWEDEN, DENMARK AND FINLAND.

Anton Paar Sweden
Phone: +46 40- 492 700
info.se@anton-paar.com

Anton Paar Denmark
Phone: +45 324 225 70
info.dk@anton-paar.com

Anton Paar Finland
Phone: +358 942 411 780
info.fi@anton-paar.com

THE SWEDISH LIFE SCIENCE INDUSTRY GUIDE 2022

715 COMPANIES – FIND YOUR BUSINESS PARTNER!

LIFE SCIENCE SWEDEN

FIND YOUR PARTNERS

The Swedish Life Science Industry Guide lists companies that either develop, produce or analyse treatments and diagnostics. It also includes companies that produce services and products essential for the development.
The Swedish life science industry is changing rapidly. To be updated visit lifesciencesweden.se/company

On the cover: MaxIV in Lund, photo by Perry Nordegren.

GALDERMA

Global Aesthetics center and Nordic sales company in Uppsala

Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin.
In Uppsala, Galderma Nordic and our global Aesthetics center of excellence reside with product development, manufacturing and marketing for world-leading products such as Restylane® and Azzalure®.

Through our journey from startup to a global company, innovation and science has always been at the core of everything we do at Galderma.

Helena Åsbrink, Head of Site Operations

GALDERMA

WEB www.galderma.com/se
www.Galdermaaesthetics.com
ADDRESS Seminariegatan 21,
SE-752 28 Uppsala
PHONE +46 18 444 0330
EMPLOYEES 5000 globally of which 500 in Sweden
FOUNDED 1981
PRINCIPAL OWNERS EQT, ADIA
PRODUCT BRANDS INCLUDES:
Basiderm®, Cetaphil®,
Epiduo®, Loceryl®, Soolantra®,
Rozaderm® etc

Company Name	Category	City	Website
Acreo Swedish ICT AB	Biotech	Kista	acreo.se
Active Biotech AB	Biotech	Lund	activebiotech.com
Acure Pharma AB	Biotech	Uppsala	acurepharma.com
Adenovir Pharma AB	Biotech	Helsingborg	adenovir.com
Affibody Holding AB	Biotech	Bromma	affibody.com
Albireo AB	Biotech	Göteborg	albireopharma.com
Alligator Bioscience AB	Biotech	Lund	alligatorbioscience.com
AlzeCure	Biotech	Huddinge	alzecure.org
AnaMar AB	Biotech	Göteborg	anamar.com
Aprea AB	Biotech	Solna	aprea.com
Asarina Pharma AB	Biotech	Solna	asarinapharma.com
AstaReal AB	Biotech	Gustavsberg	astareal.se
Athera Biotechnologies AB (publ)	Biotech	Solna	athera.se
Aurena Laboratories AB	Biotech	Karlstad	aurenalabs.com
Axcentua Pharmaceuticals AB	Biotech	Huddinge	axcentua.com
Beactica AB	Biotech	Uppsala	beactica.com
Betagenon AB	Biotech	Umeå	betagenon.com
Binab Bio-Innovation AB	Biotech	Helsingborg	binab.se
BioAgri AB	Biotech	Uppsala	bioagri.se
BioArctic Neuroscience AB	Biotech	Stockholm	bioarctic.se
Biobact AB	Biotech	Luleå	biobact.se
BioChromix Pharma AB	Biotech	Stockholm	swedishlifesciences.se/x
BioGaia AB	Biotech	Stockholm	biogaia.se
BiogenIdec Sweden AB	Biotech	Upplands Väsby	biogenidec.com
Biognos AB	Biotech	Göteborg	biognos.com
BioInvent International AB	Biotech	Lund	bioinvent.com
Bionema AB	Biotech	Umeå	mostrom.se
Biotera AB	Biotech	Lindome	biotera.se
Biovation Park	Biotech	Södertälje	biovationpark.com
Cambrex Karlskoga AB	Biotech	Karlskoga	cambrex.com/pharma
Camurus AB	Biotech	Lund	camurus.com
Capra Science Antibodies AB	Biotech	Ängelholm	caprascience.com
Cebix AB	Biotech	Solna	cebix.com

BIOTECH

Company Name	Category	City	Website
CeLac Sweden AB	Biotech	Lund	clab.se
Cellevate AB	Biotech	Lund	cellevate.com
Cellink AB	Biotech	Göteborg	cellink.com
Chemilia AB	Biotech	Huddinge	chemilia.com
CMC Contrast AB	Biotech	Malmö	cmccontrast.com
CropTailor AB	Biotech	Göteborg	croptailor.com
Crucell Sweden AB	Biotech	Stockholm	crucell.se
DanPET	Biotech	Malmö	danpet.eu
Diamyd Medical AB	Biotech	Stockholm	diamyd.se
Diamyd Therapeutics AB	Biotech	Stockholm	diamyd.com
Dilafor AB	Biotech	Solna	dilafor.com
Dilaforette AB	Biotech	Solna	dilaforette.se
Dynamic Code AB	Biotech	Linköping	dynamiccode.se
Eribis Pharmaceuticals AB	Biotech	Uppsala	eribispharma.se
Eurocine Vaccines AB	Biotech	Solna	eurocine.se
GATC Biotech AB	Biotech	Solna	gatc-biotech.com
Galderma	Biotech	Uppsala	galderma.com/se
Glucox Biotech AB	Biotech	Stockholm	glucoxbiotech.com
Hansa Medical AB (publ)	Biotech	Lund	hansamedical.com
Herbicin AB	Biotech	Lund	herbicin.com
IDL Biotech AB	Biotech	Bromma	idl.se
Immun System IMS AB	Biotech	Uppsala	immunsystem.se
Immunicum AB	Biotech	Göteborg	mmunicum.com
Indevex AB (publ)	Biotech	Storebro	indevex.com
InDex Pharmaceuticals AB	Biotech	Stockholm	indexpharma.com
Industriaktiebolaget Ventilator	Biotech	Stockholm	ventilator.se
Inhalation Sciences Sweden AB	Biotech	Huddinge	inhalation.se
Intervacc AB	Biotech	Hägersten	intervacc.com
Isconova AB	Biotech	Uppsala	isconova.se
Isifer AB	Biotech	Danderyd	isifer.se
Kancera AB	Biotech	Solna	kancera.com
Karo Bio AB	Biotech	Huddinge	karobio.se
Lavivo AB	Biotech	Västra Frölunda	lavivo.com
LIDDS AB	Biotech	Helsingborg	liddspharma.com
Lipum AB	Biotech	Umeå	lipum.se
Magle AB	Biotech	Lund	magle.se
Meda AB	Biotech	Solna	meda.se
Mercodia AB	Biotech	Uppsala	mercodia.com
Microbionical	Biotech	Lund	microbionical.com
MIVAC Development AB	Biotech	Göteborg	mivacdevelopment.com
NeuroNova AB	Biotech	Stockholm	neuronova.com
NeuroVive Pharmaceutical AB	Biotech	Lund	neurovive.com
Newpharmaresearch AB	Biotech	Lund	newpharma.se
NicoNovum AB	Biotech	Helsingborg	niconovum.se
Nordic Drugs AB	Biotech	Limhamn	nordicdrugs.com
NovaHep AB	Biotech	Stockholm	novahep.com
NovaSAID AB	Biotech	Solna	novasaid.com
OdeumPharma AB	Biotech	Billdal	odeumpharma.se
Omnio Healer AB	Biotech	Umeå	omniohealer.com
Oncopeptides AB	Biotech	Stockholm	oncopeptides.se

Company Name	Category	City	Website
Orexo AB	Biotech	Uppsala	orexo.com
OxyPharma AB	Biotech	Stockholm	oxypharma.com
Pergamum AB	Biotech	Solna	pergamum.com
Pharmalink AB	Biotech	Stockholm	pharmalink.se
PharmaSurgics in Sweden AB	Biotech	Göteborg	pharmasurgics.se
PledPharma AB	Biotech	Stockholm	pledpharma.se
Ponsus Pharma	Biotech	Vallentuna	ponsus.com
Probac AB	Biotech	Umeå	probac.se
Probi AB	Biotech	Lund	probi.com
ProEquo AB	Biotech	Lund	proequo.se
QureTech Bio AB	Biotech	Umeå	quretech.com
Red Glead Discovery AB	Biotech	Lund	redglead.com
Respiratorius AB	Biotech	Lund	respiratorius.com
SARomics Biostructures AB	Biotech	Lund	saromics.com
ScanBi Diagnostics AB	Biotech	Alnarp	scanbidiagnostics.com
SentoClone International AB	Biotech	Stockholm	sentoclone.com
Spago Nanomedical AB	Biotech	Lund, Sweden	spagonanomedical.se
Sprint Bioscience AB	Biotech	Stockholm	sprintbioscience.com
Sweden AB	Biotech	Göteborg	irlab.se
SweTree Technologies AB	Biotech	Umeå	swetree.com
Symbioteq vård AB	Biotech	Kista	symbioteq.se
Takara Bio Europe AB (Cellartis)	Biotech	Göteborg	cellartis.com
TikoMED AB	Biotech	Viken	tikomed.com
Transientic Interactions AB	Biotech	Sigtuna	transientic.com
Umecrine AB	Biotech	Umeå	obgyn.umu.se
Vicore Pharma AB	Biotech	Göteborg	vicorepharma.com
Wilson Therapeutics AB	Biotech	Stockholm	wilsontherapeutics.com
Xintela AB	Biotech	Lund	xintela.se

MEDTECH

Company Name	Category	City	Website
A. Menarini Diagnostics	Medtech	Malmö	menarinidiagnostics.se
AbSorber AB	Medtech	Stockholm	absorber.se
AD MediCal AB	Medtech	Göteborg	ad-medical.se
AddBIO AB	Medtech	Linköping	addbio.se
Aerocrine AB	Medtech	Solna	aerocrine.com
Airsonett	Medtech	Ängelholm	airsonett.com
Alere AB	Medtech	Lidingö	alere.com
Allenex AB	Medtech	Stockholm	allenex.se
Aloro Medical AB	Medtech	Solna	aloromedical.com
Alteco Medical AB	Medtech	Lund	altecomedical.com
Amellnova AB	Medtech	Uppsala	amellnova.se
Aniara Corporation	Medtech	Katrineholm	aniara.com
Aprovix AB	Medtech	Uppsala	aprovix.se
AroCell AB	Medtech	Uppsala	arocell.com
Aspira Medical AB	Medtech	Borlänge	aspira.se
AstraTech AB	Medtech	Mölndal	astratech.com
B. Braun Medical AB	Medtech	Danderyd	bbraun.com
Baxter Medical AB – BioScience Division	Medtech	Kista	baxter.se
BioChromix AB	Medtech	Stockholm	biochromix.com
bioMérieux Sweden AB	Medtech	Askim	biomerieux.com
Biovica AB	Medtech	Uppsala	biovica.com
Bohus BioTech AB	Medtech	Strömstad	bohusbiotech.com
Bone Support AB	Medtech	Lund	bonesupport.com
Boule Diagnostics AB	Medtech	Stockholm	boule.se
Brighter AB (publ)	Medtech	Stockholm	BrighterCompany.com
Cambio	Medtech	Stockholm	cambio.se
Carmeda AB	Medtech	Upplands Väsby	carmeda.com
Cavidi AB	Medtech	Uppsala	cavidi.se
CellaVision AB	Medtech	Lund	cellavision.se
Cellwell	Medtech	Åkersberga	cellwell.se
Cenova AB Innovation & Production	Medtech	Mjölby	cenova.se
Cepheid AB	Medtech	Bromma	affigene.com
Cerner	Medtech	Stockholm	cerner.com
Cewatech AB	Medtech	Göteborg	cewatech.se
Coloplast A/S Humlebaek	Medtech	Danmark	coloplast.se
Comair Professor Hans Wiksell AB	Medtech	Stockholm	comair.se
Corline Systems AB	Medtech	Uppsala	corline.com
CR Development	Medtech	Lund	colloidalresource.se
Cubist IT AB	Medtech	Stockholm	cubist.eu
Demetech AB	Medtech	Täby	demetech.com
Devyser AB	Medtech	Stockholm	devyser.com
Diamyd Diagnostics AB	Medtech	Stockholm	diamyd.com
DiaSorin AB	Medtech	Sundbyberg	diasorin.com
Doxa AB	Medtech	Uppsala	doxa.se
Elekta	Medtech	Stockholm	elekta.com
Entomed AB	Medtech	Malmö	entomed.se
Euro-Diagnostica AB	Medtech	Malmö	eurodiagnostica.se
Finess Hygiene AB	Medtech	Kisa	finesshygiene.com
Fresenius Medical Care	Medtech	Stockholm	freseniusmedicalcare.se

MEDTECH

Company Name	Category	City	Website
Fujirebio Diagnostics AB	Medtech	Göteborg	fdab.com
GCE Healthcare	Medtech	Malmö	gcehealthcare.com
Getinge	Medtech	Göteborg	getinge.com
Glycorex Transplantation AB	Medtech	Lund	glycorex.com
Gynius AB	Medtech	Stockholm	gynius.se
Haemochrom Diagnostica AB	Medtech	Mölndal	haemochrom.se
Hermes Medical Solutions AB	Medtech	Stockholm	hermesmedical.com
Hilotherm Scandinavia	Medtech	Täby	hilotherm.se
Höjmed Medical AB	Medtech	Stockholm	hojmed.com
Imego AB	Medtech	Göteborg	imego.com
Inpart Trading AB	Medtech	Vagnhärad	inparttrading.se
InRo BioMedTek AB	Medtech	Umeå	inro.se
Johnson & Johnson	Medtech	Stockholm	jnj.com
Kibion AB	Medtech	Uppsala	kibion.se
Laccure AB	Medtech	Helsingborg	laccure.com
LifeAssays AB	Medtech	Lund	lifeassays.com
Likvor AB	Medtech	Umeå	likvor.com
LinkoCare Life Sciences AB	Medtech	Linköping	linkocarelife.com
MedHelp	Medtech	Stockholm	medhelp.se
Medicvent AB	Medtech	Umeå	medicvent.se
Mediplast AB	Medtech	Malmö	mediplast.com
MediRox AB	Medtech	Nyköping	medirox.se
MEDWIND	Medtech	Kungsbacka	medwind.se
Mentice AB	Medtech	Göteborg	mentice.com
Miab Mälarinvest AB	Medtech	Uppsala	phadia.com
Micropos Medical AB (publ)	Medtech	Gothenburg	micropos.se
Neoventa Medical AB	Medtech	Mölndal	neoventa.com
Nidacon International AB	Medtech	Mölndal	nidacon.com
Nolabs AB	Medtech	Helsingborg	nolabs.com
Nordic Biomarker	Medtech	Umeå	nordicbiomarker.com
Novosense AB	Medtech	Lund	novosense.se
Olerup SSP AB	Medtech	Saltsjöbaden	olerupssp.se
Omnio AB	Medtech	Umeå	omnio.se
OneMed	Medtech	Stockholm	onemed.se
Ortivus	Medtech	Stockholm	ortivus.com
Ortoway AB	Medtech	Stockholm	ortoway.com
Osseofon AB	Medtech	Göteborg	chalmers.se
Osstell AB	Medtech	Göteborg	osstell.com
Otorix AB	Medtech	Askim	otorix.com
Phadia AB	Medtech	Uppsala	phadia.com
Pharmacolog i Uppsala AB	Medtech	Uppsala	pharmacolog.se
Philips healthcare	Medtech	Stockholm	philips.se/healthcare
PhPlate AB	Medtech	Stockholm	phplate.se
Polymer Factory Sweden AB	Medtech	Nacka	polymerfactory.com
PreCuris	Medtech	Stockholm	precuris.com
Prolight Diagnostics AB	Medtech	Lund	pldab.com
Promimic	Medtech	Göteborg	promimic.se
QAdvis AB	Medtech	Kista	qadvis.com

MEDTECH

Company Name	Category	City	Website
Qbtech AB	Medtech	Stockholm	qbtech.se
Redsense Medical	Medtech	Halmstad	redsensemedical.com
Roche Diagnostics Scandinavia AB	Medtech	Bromma	roche.se
Rossix AB	Medtech	Mölndal	rossix.com
SAGA Diagnostics AB	Medtech	Lund	sagadiagnostics.com
Scalae AB	Medtech	Dalby	scalae.se
SciBase AB	Medtech	Stockholm	scibase.se
Senzime AB	Medtech	Uppsala	senzime.com
SHL Group AB	Medtech	Nacka Strand	shl-group.net
SHL Technologies	Medtech	Nacka Strand	shl-group.com
Siemens Healthcare Diagnostics AB	Medtech	Upplands Väsby	siemens.com/diagnostics
Silentia	Medtech	Falkenberg	silentia.se
Swemac Medical Appliances AB	Medtech	Linköping	swemacimaging.com
Symbioteq kvalitet AB	Medtech	Kista	symbioteq.se
SyntheticMR AB	Medtech	Linköping, Sweden	syntheticmr.se
Tieto	Medtech	Stockholm	tieto.com
Tilly Medical Products AB	Medtech	Lund	tmed.se
Vitrolife AB	Medtech	Göteborg	vitrolife.com
XCounter AB (publ)	Medtech	Danderyd	xcounter.se
Össur Nordic AB	Medtech	Uppsala	ossur.com

ASTRAZENECA

What Science can do

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com, astrazeneca.se and follow the Company on Twitter @AstraZeneca, @AstraZenecaSE

"By harnessing the unprecedented possibilities of science and technology, by transforming the way we work and by engaging with patients in everything we do, I am confident that we will realise our pipeline's potential to the full and deliver continued success.

Pascal Soriot, CEO

WEB www.astrazeneca.se
ADDRESS 151 85 Södertälje, Sweden
PHONE +46 (0) 8 553 260 00
E-MAIL kontakt@astrazeneca.com
REVENUE 24,4 BILLION USD (2019)
EMPLOYEES 70 600 (2019)
FOUNDED 1999
(Astra founded 1913)
PUBLIC/LIST: London, Stockholm and New York
CHAIRMAN Leif Johansson
PRINCIPAL OWNERS BlackRock, Inc., Wellington Management Group LLP, Investor AB, The Capital Group

Company Name	Category	City	Website
Abbott Scandinavia AB	Pharma	Solna	abbott.com
Abigo Medical AB	Pharma	Askim	abigo.com
Amgen AB	Pharma	Solna	amgen.com
AstraZeneca AB	Pharma	Södertälje	astrazeneca.se
Bristol Myers Squibb	Pharma	Stockholm	bms.com
Dinamediciner.se	Pharma	Stockholm	dinamediciner.se
Fresenius Kabi AB	Pharma	Uppsala	fresenius-kabi.se
Idogen	Pharma	Lund	idogen.se
Karessa	Pharma	Stockholm	karessa.se
Medeca Pharma AB	Pharma	Uppsala	medeca.se
Medivir AB	Pharma	Stockholm	medivir.se
Merck AB	Pharma	Solna	merck.se
Moberg Derma AB	Pharma	Solna	mobergderma.se
Octapharma AB	Pharma	Stockholm	octapharma.se
Orexo	Pharma	Uppsala	orexo.com
Pfizer	Pharma	Stockholm	pfizer.se
Pharmanest AB	Pharma	Solna	pharmanest.se
Pledpharma	Pharma	Stockholm	pledpharma.se
Recipharm	Pharma	Stockholm	recipharm.com
Redwood Pharma AB	Pharma	Stockholm	redwoodpharma.se
Roche	Pharma	Stockholm	roche.se
Sanofi	Pharma	Bromma	sanofi.se
Stayble Therapeutics	Pharma	Göteborg	stayletherapeutics.se
Swedish Orphan Biovitrum AB	Pharma	Stockholm	sobi.com
Vivolux AB	Pharma	Uppsala	vivolux.com

BUSINESS DEVELOPMENT & SERVICES

IQVIA

Solutions for you to drive healthcare forward

IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 80,000 employees, IQVIA conducts operations in more than 100 countries.

We can through leading healthcare big data and technologies, combined with deep scientific and commercial expertise, help find unparalleled insights, and support our clients from molecule to market.

Stefan Ohlsson, General Manager Nordics

WEB www.iqvia.com
ADDRESS Pyramidvägen 7, 169 56 Solna
PHONE +46 8 50884200
E-MAIL contact_nordics@iqvia.com
EMPLOYEES 80.000 global where of 600 in the Nordics
FOUNDED 2016 through the merger of IMS Health and Quintiles
PUBLIC COMPANY Yes, NYSE
CHAIRMAN Ari Bousbib

KEYPLANTS AB

Solutions that make a difference

KeyPlants, headquartered in Stockholm, manage the design, construction, and commissioning of life science facilities to demanding customers in Sweden and globally. Our core competences include project management, process design, facility design, automation, construction management, commissioning, and qualification. We also provide subject matter expertise in biomanufacturing, aseptic filling, containment and manufacturing of APIs and oral solids. Our team of skilled and experienced engineers clearly makes a difference. Furthermore, as the global modular off-site construction leader, we provide unrivalled modular design and execution experience and capability. Our modular facilities are manufactured in Sweden. We will simplify your facility project and execute the project with speed, flexibility, and predictability.

Our vision is to be the leading provider of innovative life science facilities.

Jörgen Harrysson, Managing Director/CEO

WEB www.keyplants.com
ADDRESS Lilla Bantorget 15, 111 23 Stockholm
PHONE +46 8 684 56 200
E-MAIL info@keyplants.com
EMPLOYEES 120
FOUNDED 2010
PUBLIC COMPANY No

MEDEON AB

The best location in Medicon Valley

Medeon Science Park & Incubator provides a creative environment for new and established companies. Our focus is directed at knowledge-intensive businesses within life science: pharmaceutical development, medical technology, biotechnology and health care.
At Medeon you gain access to:

- Suitable premises with the opportunity to build new facilities.
- Close cooperation with health care and the University.
- Strong network and incubator functions.
- Life Science specific business development, visibility and internationalisation. Good services with, for example, reception, switchboard, travel agency and restaurant.

The science park for the life sciences & health

Ulf G Andersson, CEO

WEB www.medeon.se
ADDRESS Medeon AB
Medeon Science Park & Incubator
205 12 Malmö, Sweden
PHONE +46 703-052565
E-MAIL
catrine.pauckstadt@medeon.se
REVENUE N/A
EMPLOYEES 3
FOUNDED 1985
PUBLIC COMPANY No
CHAIRMAN N/A
PRINCIPAL OWNERS N/A

MEDICON VALLEY ALLIANCE

– where Swedish and Danish life science ambitions intersect!

The certified Gold Labelled life science cluster organization, Medicon Valley Alliance (MVA) is a non-profit member-based organization located in the Swedish-Danish Medicon Valley region (Southern Sweden & Eastern Denmark). Medicon Valley Alliance has 300+ member companies and institutions including Swedish and Danish universities, hospitals, life science businesses, industrial parks and incubators, CMOs, CROs, regional governments and service providers. Through networking, project management, life science professional seminars, events and conferences, MVA initiates and facilitates Swedish-Danish life science collaborations and contributes to the positioning and strengthening of Medicon Valley as the most competitive and attractive life science cluster in Northern Europe.

By strengthening our life science region: Medicon Valley, we will be making 1 + 1 become 3 – benefitting not just the region but also the entire Swedish and the entire Danish life science eco-systems and societies moving Nordic life science up the world-class rankings.

Anette Steenberg, CEO of Medicon Valley Alliance

medicon valley alliance
Creating Opportunities

WEB www.mva.org
ADDRESS Arne Jacobsens Allé 15, 2. Ørestad City, DK-2300 Copenhagen S Denmark
PHONE +45 70 20 15 03
E-MAIL mva@mva.org
EMPLOYEES 12
FOUNDED 1997
CHAIRMAN Søren Bregenholt

PHARM ASSIST SWEDEN AB

Quality Assurance and Regulatory Affairs professional services

Pharm Assist is a professional service company offering quality and regulatory solutions for medicinal products and medical device. Founded in 1996 the company has assisted more than 250 pharmaceutical and medtech companies over the years. Our qualified team which has deep scientific, business and regulatory experience is providing tailor-made professional services in quality assurance and regulatory affairs to local and international pharma, biotech and medtech companies. Examples of services offered by us are pharmacovigilance (incl. QPPV), Good Distribution Practice (incl. RP), scientific and regulatory writing, RA support and product life cycle management, medical information and labelling, data base management, registrations, and QA/RA and advisory services relating to medical devices including clinical investigations (MDR and IVDR).

Pharm Assist's highly qualified team provides solutions that minimize patient risk, ensure regulatory compliance and drive operational effectiveness.

Johan von Heijne, CEO

pharm assist
Our team. Your solution.

WEB www.pharmassist.se
ADDRESS Pharm Assist Sweden AB, Fyristorg 6, 753 10 Uppsala, Sweden
PHONE +46 (0)18 71 32 00
FOUNDED 1996
PRIVATE COMPANY

SCANDINAVIAN DEVELOPMENT SERVICES

Services that make a difference

SDS Life Science is the leading consultancy in the Nordics with regards to regulatory guidance, design of clinical trials and expertise in biostatistics. We help clients develop pharmaceuticals, combination products and medical device from early phase to exit or market. Our concept is to offer services within the full spectrum of competences needed for drug development. A dedicated team of experts with solid background and experience from working at regulatory agencies, pharma industry and academia work together to create value by delivering the most efficient development program.

Our distinction is our multidisciplinary approach. We call it the SDS difference!

Gösta Hiller PhD, CEO.

sds Life Science

WEB www.scanddev.se
ADDRESS Svärdvägen 23, SE 281 33 Danderyd, Sweden (HQ)
PHONE +46 (0)8 755 80 80
E-MAIL contact@sdslifescience.com
REVENUE 60 mSEK
EMPLOYEES 35
FOUNDED 2012
PUBLIC COMPANY No
CHAIRMAN Jens Hansson
PRINCIPAL OWNER Anna Törner

BUSINESS DEVELOPMENT & SERVICES

Company Name	Category	City	Website
@hiveandfive	Business Devel/Service	Borås	hiveandfive.se
Accelerator Nordic AB	Business Devel/Service	Stockholm	acceleratorab.se
Adapt Localization Services	Business Devel/Service	Stockholm	adapt-localization.com
Advokatfirman Delphi	Business Devel/Service	Stockholm	delphi.se
Aktivia Science Work AB	Business Devel/Service	Huddinge	sciencework.nu
Aldenco AB	Business Devel/Service	Huddinge	aldenco.se
ALS Scandinavia AB	Business Devel/Service	Luleå	alsglobal.se
Alumni AB	Business Devel/Service	Stockholm	alumni.se
Animech AB	Business Devel/Service	Uppsala	animech.com
Animech Technologies	Business Devel/Service	Uppsala	animechtechnologies.com
AnoxKaldnes Global AB	Business Devel/Service	Lund	anoxkaldnes.com
Antaros Medical AB	Business Devel/Service	Mölndal	antarosmedical.com
Arthur D. Little AB	Business Devel/Service	Stockholm	adlittle.com
Ashfield Nordic AB (formerly known as Pharmexx Nordic AB)	Business Devel/Service	Stockholm	ashfieldhealthcare.com
AssuransSelector AB	Business Devel/Service	Helsingborg	assuransselector.se
Berendsen Textil Service AB	Business Devel/Service	Nyköping	berendsen.se
BioMedLit	Business Devel/Service	Järfälla	biomedlit.com
BioPharmaLinx AB	Business Devel/Service	Bromma	biopharmalinx.se
BioReach AB	Business Devel/Service	Uppsala	bioreach.se
Bioventia AB	Business Devel/Service	Uppsala	bioventia.com
BiQ Pharma AB	Business Devel/Service	Södertälje	biqpharma.com
Bondi Executive Search	Business Devel/Service	Stockholm	bondi.se
Bruun & Maté AB	Business Devel/Service	Malmö	bruunmate.com
Business Region Göteborg-FDI-Life Science	Business Devel/Service	Göteborg	businessregiongoteborg.com
Cardell Consulting AB	Business Devel/Service	Sollentuna	cardellconsulting.com
Chemnotia AB	Business Devel/Service	Bromma	chemnotia.com
Chubb Insurance Company of Europe S.A.	Business Devel/Service	Stockholm	chubb.com/international/se
CITEC	Business Devel/Service	Karlstad	citec.com
Clean Room Control AB	Business Devel/Service	Uppsala	cr-control.se
ClinStorage AB	Business Devel/Service	Solna, Sweden	clinstorage.se
Compass Rekrytering & Utveckling AB	Business Devel/Service	Stockholm	compass.se
Copenhagen Bio Science Park	Business Devel/Service	Copenhagen N	cobis.dk
Damn Good Agency	Business Devel/Service	Stockholm	dga.se
Devex Mekatronik AB	Business Devel/Service	Skarpnäck, Stockholm	devexmekatronik.se
Devex ProPart AB	Business Devel/Service	Skarpnäck, Stockholm	devex.se
Dfind Science & Engineering AB	Business Devel/Service	Stockholm	dfind.se/science-engineering
DHL Express Nordic	Business Devel/Service	Stockholm	dhl.com
Docs International	Business Devel/Service	Solna	docs-int.se
Edsman Medical Writing	Business Devel/Service	Stockholm	edmedica.se
Elpro Nordic ApS	Business Devel/Service	Hørsholm	elpro.com
Encecor AB	Business Devel/Service	Uppsala	encecor.com
Epsilon AB	Business Devel/Service	Malmö	epsilon.nu
Ernst & Young AB	Business Devel/Service	Stockholm	se.ey.com
Etteplan	Business Devel/Service	Västerås	protang.se
Etteplan Sweden AB	Business Devel/Service	Halmstad	etteplan.com
Eureda	Business Devel/Service	Uppsala	eureda.com
Exova Metech AB	Business Devel/Service	Linköping	exovametech.se
Extero AB	Business Devel/Service	önköping	extero.se
FindFactPharma AB	Business Devel/Service	Mariefred	findfactpharma.se

BUSINESS DEVELOPMENT & SERVICES

Company Name	Category	City	Website
ForValue AB	Business Devel/Service	Göteborg	forvalue.se
Galenometrics AB	Business Devel/Service	Uppsala	linkedin.com/in/Galenometrics
GATC Biotech AB	Business Devel/Service	Solna	gatc-biotech.com
Global Pharma Consulting AB	Business Devel/Service	Johanneshov	globalpharma.se
Greenhouse Labs	Business Devel/Service	Stockholm	greenhouselabs.che.kth.se
Healthy Bizniz Europe AB	Business Devel/Service	Strängnäs	healthybizniz.eu
HotSwap	Business Devel/Service	Sundbyberg	hotswap.eu
Imdevco AB	Business Devel/Service	Göteborg	telia.com
InfoTech Scandinavia AB	Business Devel/Service	Malmö	advantum.com
Innoventus Project AB	Business Devel/Service	Uppsala	innoventus.com
International Clinical Testing AB	Business Devel/Service	Ljusdal	clinicaltesting.se
Invest in Skåne	Business Devel/Service	Malmö	investinskane.com
IQVIA	Business Devel/Service	Solna	iqvia.com
J.F.B Consulting AB	Business Devel/Service	Hisings Backa	jfb-consulting.com
JLT Risk Solutions AB	Business Devel/Service	Stockholm	jltrisk.se
Kamishi AB	Business Devel/Service	Stockholm	kamishi.se
Karolinska Institutet Science Park	Business Devel/Service	Solna	sciencepark.ki.se
Karolinska Development AB	Business Devel/Service	Solna	karolinskadevelopment.com
Karolinska Institutet Innovations AB	Business Devel/Service	Solna	kiinnovations.se
KeyPlants AB	Business Devel/Service	Stockholm	keyplants.com
Know IT Business Consulting AB	Business Devel/Service	Stockholm	knowit.se
Kuehne + Nagel AB	Business Devel/Service	Kista	kn-portal.com
Labjoy AB	Business Devel/Service	Lund	labjoy.se
Landegren Gene Technology AB	Business Devel/Service	Uppsala	igp.uu.se
Lidingö Elektriska	Business Devel/Service	Lidingö	lidingoelektriska.se
Logos - global language service provider to the life sciences industry	Business Devel/Service	Ystad	logos.net
LucyJRobertshaw	Business Devel/Service	Hölö	lucyjrobertshaw.com
Mandalon Technologies AB	Business Devel/Service	Linköping	mandalon.se
Mandly Search & Selection	Business Devel/Service	Stockholm	mandly.se
Marken Ltd.	Business Devel/Service	Stockholm-Arlanda	marken.com
MD Medical Writing & Translations	Business Devel/Service	Hammenhög	mariadalby.com
Medeon AB	Business Devel/Service	Malmö	medeon.se
Medical Lead Nordic AB	Business Devel/Service	Stockholm	medicallead.se
Medicon Valley Alliance	Business Devel/Service	Copenhagen	mva.org
Medicon Village	Business Devel/Service	Lund	mediconvillage.se
MediGelium AB	Business Devel/Service	Stockholm	sciencepark.ki.se/node/125
Medmind	Business Devel/Service	Stockholm	medmind.se
Medos AB	Business Devel/Service	Linköping	medos.se
Merrill Brink International	Business Devel/Service	Torslanda	merrillbrink.com
MetaSafe AB	Business Devel/Service	Södertälje	metasafe.se
Mikrolab Stockholm AB	Business Devel/Service	Sollentuna	vattenprovtagning.se
Minerva Sverige AB	Business Devel/Service	Kista	minerva-plm.com/minerva-group
Mintage Scientific AB	Business Devel/Service	Göteborg	mintage.se
Mizarra Business Management	Business Devel/Service	Helsingborg	mizarra.com
Monocl AB	Business Devel/Service	Göteborg	monocl.com
Montex AB	Business Devel/Service	Jämjö	montex.se
Moveup Consulting AB	Business Devel/Service	Göteborg	moveup.se
N4 Teknik AB	Business Devel/Service	Södertälje	n4.nu
NDA Group AB	Business Devel/Service	Upplands Väsby	ndareg.com
NNE Pharmaplan AB	Business Devel/Service	Stockholm	nnepharmaplan.com
Nordic Life Science Corporate Finance AB	Business Devel/Service	Stockholm	nordiclifescience.com

BUSINESS DEVELOPMENT & SERVICES

Company Name	Category	City	Website
Notch Communications AB	Business Devel/Service	Uppsala	notchcommunications.co.uk
NY Consulting AB	Business Devel/Service	Lund	nyconsulting.se
Oasmia Pharmaceutical AB	Business Devel/Service	Uppsala	oasmia.com
OffspringBiosciences AB	Business Devel/Service	Södertälje	offspringbiosciences.se
Ola Levin Consulting AB	Business Devel/Service	Lidingö	levinpharma.se
Oncodesign SA	Business Devel/Service	Dijon - France	oncodesign.com
Oxyma Innovation AB	Business Devel/Service	Solna	oxyma.se
P.U.L.S. AB	Business Devel/Service	Helsingborg	pulsinvest.se
Parmatur HB	Business Devel/Service	Rönninge	parmatur.com
PeakSearch AB	Business Devel/Service	Stockholm	peaksearch.se
Peter Utterström	Business Devel/Service	Saltsjöbaden	swedishlifesciences.se/X
Pharma Relations AB	Business Devel/Service	Kista	pharmarelations.se
Pharma Search and Advice AB	Business Devel/Service	Stockholm	pharmasearch.se
Pharmadrome Ltd	Business Devel/Service	London	pharmadrome.com
PharmaSite	Business Devel/Service	Malmö	pharmasite.se
Pharm Assist Sweden AB	Business Devel/Service	Uppsala	pharmassist.se
Poolia Life Science	Business Devel/Service	Stockholm	poolia.se
Prevas AB	Business Devel/Service	Uppsala	prevas.se
Projektgruppen i Mälardalen AB	Business Devel/Service	Sollentuna	projektgruppen.com
Projektsupport S-O AB	Business Devel/Service	Lund	projektsupportso.com
ProPharma Group	Business Devel/Service	Stockholm	ProPharmaGroup.com
Q Advance Compliance & Validation AB	Business Devel/Service	Uppsala	qadvance.se
QAdvis AB	Business Devel/Service	Kista - Lund	qadvis.com
QMP Quality Maintenance Partner AB	Business Devel/Service	Tyresö	qmp.se
Raise-In AB	Business Devel/Service	Älvsjö	raise-in.se
Ramidus AB	Business Devel/Service	Lund	ramidus.se
RegSafe - Regulatory Safety Sciences	Business Devel/Service	Stocksund	regsafe.se
Sahlgrenska Science Park	Business Devel/Service	Göteborg	sahlgrenskasciencepark.se
Scandinavian Development Services	Business Devel/Service	Danderyd	scanddev.se
Scandinavian Regulatory Services AB	Business Devel/Service	Danderyd	srs.se
Scientific Solutions Scandinavia AB	Business Devel/Service	Stockholm	scientificsolutions.se
Scientific Work	Business Devel/Service	Nacka	scientificwork.se
Semcon	Business Devel/Service	Göteborg	semcon.com
Senator Medical AB	Business Devel/Service	Upplands-Bro	senatormedical.se
Serviceföretaget PIMA AB	Business Devel/Service	Södertälje	pima.se
SIS, Swedish Standards Institute	Business Devel/Service	Stockholm	sis.se
Sjukvårdsekonomi	Business Devel/Service	Lund	ihe.se
Skogsmöllan AB	Business Devel/Service	Veberöd	skogsmollan.se
SLS Invest AB	Business Devel/Service	Stockholm	slsinvest.com
SLU Holding AB	Business Devel/Service	Uppsala	slu.se
Smile Incubator	Business Devel/Service	Lund	smileincubator.life
SOBC Sweden	Business Devel/Service	Vårby	vimsson.com
SP Process Development	Business Devel/Service	Södertälje	sp.se
Stockholm Business Region	Business Devel/Service	Stockholm	stockholmbusinessregion.se
Stockholm Science City Foundation	Business Devel/Service	Stockholm	ssci.se
Stockholm-Uppsala Life Science	Business Devel/Service	Uppsala	suls.se
Strategic Research	Business Devel/Service	Stockholm	stratresearch.se
Swedish Labtech	Business Devel/Service	Stockholm	swedishlabtech.se
Symbio AB	Business Devel/Service	Stockholm	endevo.se
Synergus	Business Devel/Service	Täby	synergus.se
Tambiz Consulting	Business Devel/Service	Stockholm	tambiz.se
TATAA Biocenter AB	Business Devel/Service	Göteborg	tataa.com
Technia AB	Business Devel/Service	Kista	technia.se

BUSINESS DEVELOPMENT & SERVICES

Company Name	Category	City	Website
Teknopol AB	Business Devel/Service	Lund	teknopol.se
TeknoSeed AB	Business Devel/Service	Lund	teknoseed.se
TNS SIFO Navigare	Business Devel/Service	Gothenburg	navigare.se
Tools of Science	Business Devel/Service	Stockholm	toolsofscience.se
Toxicology Knowledge Team Sweden AB	Business Devel/Service	Södertälje	toxkteam.com
Trialbee AB	Business Devel/Service	Lund	trialbee.com
Trust forwarding	Business Devel/Service	Stockholm	trustforwarding.se
TSS AB	Business Devel/Service	Stockholm	tss.se
UK Trade & Investment	Business Devel/Service	Stockholm	ukti.gov.uk
Umeå Biotech Incubator	Business Devel/Service	Umeå	ubi.se
Unilabs AB	Business Devel/Service	Göteborg	capiodiagnostik.se
Uppsala BIO	Business Devel/Service	Uppsala	uppsalabio.se
UUAB Utveckling AB	Business Devel/Service	Uppsala	uuab.uu.se
Validera	Business Devel/Service	Kista	validera.se
Ventac Partners AB	Business Devel/Service	Lund	ventac-partners.com
Veprox Medical	Business Devel/Service	Västra Frölunda	veprox.se
Visipower	Business Devel/Service	Lomma	visipower.com
World Courier (Sweden) AB	Business Devel/Service	Arlandastad	worldcourier.com
Wusson Accelerator AB	Business Devel/Service	Stockholm	wusson.com
YIT Sverige AB	Business Devel/Service	Solna	yit.se
Your Special Delivery Service AB	Business Devel/Service	Stockholm	ysds.com/sv

BIOIT

Company Name	Category	City	Website
Aitellu Technologies AB	BioIT	Gothenburg	aitellu.com
Bytewize AB	BioIT	Västerås	bytewize.com
Capish	BioIT	Malmö	capishknowledge.com
Clinical Gene Networks	BioIT	Stockholm	clinicalgenenetworks.com
Compumine AB	BioIT	Uppsala	compumine.com
Comsol AB	BioIT	Stockholm	comsol.com
Contur Software AB	BioIT	Stockholm	contur.com
Formpipe Software AB	BioIT	Stockholm	formpipe.com
HealthiHabits	BioIT	Stockholm	healthihabits.com
IP Life Sciences AB/IPERION	BioIT	Lund	iperion.se
Just-In-Mind AB	BioIT	Stockholm	just-in-mind.se
Labstory	BioIT	Borlänge	labstory.se
LabWare Nordic	BioIT	Helsingborg	labware.com
MedicWave AB	BioIT	Halmstad	medicwave.com
MKS Umetrics AB	BioIT	Umeå	umetrics.com
MultiD Analyses AB	BioIT	Göteborg	multid.se
Nagarro Software	BioIT	Kista	nagarro.com
Proxedra	BioIT	Tyresö	proxedra.com
Qlucore	BioIT	Lund	qlucore.com
Software Point AB	BioIT	Danderyd	softwarepoint.com
Starlims Nordic	BioIT	Danderyd	starlims.com
Stratiteq Sweden AB	BioIT	Malmö	stratiteq.com
The MathWorks	BioIT	Kista	mathworks.com

PCI PHARMA SERVICES

PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products' speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients' lives. #LetsTalkFuture™

We are the trusted partner for pharmaceutical and biopharmaceutical customers, providing clinical and commercial supply chain solutions in the shared goal of improving patients' lives.

Salim Haffar, CEO

WEB www.pci.com
ADDRESS PCI Pharma Services Germany, GmbH, Am Wall 5, D-14979 Großbeeren (Berlin)
PHONE +49 151 61 5757 32
E-MAIL talkfuture@pciservices.com
EMPLOYEES 4500 globally

Company Name	Category	City	Website
APL (Apotek Produktion & Laboratorier AB)	CMOs	Kungens Kurva	apl.se
Bioglan AB	CMOs	Malmö	bioglan.se
Cobra Biologics	CMOs	Matfors	cobrabio.com
Galenica AB	CMOs	Malmö	galenica.se
Kemwell AB	CMOs	Uppsala	kemwellbiopharma.com
Medicago AB	CMOs	Uppsala	medicago.se
PCI Pharma Services	CMOs	Berlin	pci.com
Pfizer Health AB, Site Strängnäs	CMOs	Strängnäs	pfizer.se
QPharma AB	CMOs	Malmö	qpharma.se
Recipharm AB	CMOs	Jordbro	recipharm.com
Zelmic AB	CMOs	Lund	zelmic.se

CRO

A+ SCIENCE AB

Earn Trust - Make Difference

A+ Science is a Contract Research Organisation (CRO) run by its employees. We provide services in clinical trials for pharmaceuticals (phase I-IV) and medical devices. For more than two decades we have been performing clinical trials for small, mid-size and big pharmaceutical, biotech and medical device companies. We also offer broad expertise in pharmacovigilance (PV) services both during clinical trials and after marketing authorization, such as EU/UK QPPV, signal management and PV audits. We offer customised, flexible and cost-efficient solutions to our clients.

Our core expertise is in the Nordic Countries, however through our close collaboration and partnership with other CROs, we cover several other countries.

Our vision is to earn trust and make difference.

Håkan Fröderberg, CEO

WEB www.a-plusscience.com
ADDRESS Luntmakargatan 22, 111 37 Stockholm, Sweden
PHONE +46 (0) 73 67 44 122
E-MAIL info@a-plusscience.com
REVENUE 18 MSEK
EMPLOYEES 14
FOUNDED 1997
PUBLIC COMPANY Public but not listed
CHAIRMAN Mikael Nordenstjerna

ADLEGO BIOMEDICAL AB

Adlego Biomedical – Your preclinical partner

Adlego Biomedical ABs customers are always guaranteed honest project discussions and reports. Medical Product Agencies rely on the independence and integrity of Adlego! We collaborate with a complete range of companies to cover all parts of preclinical drug development.
Adlego Biomedical AB is a proud member of Karolinska Institutet Science park.



Twe work virtually, in collaboration with other small CROs, we care about small specialized projects, but have also capacity for long-term projects. Our customers appreciate short lead times and direct communication with Study Directors.

Urban Höglund, CEO

WEB www.adlego.se
ADDRESS P.O. Box 42, 751 03 Uppsala, Sweden
PHONE +46 (0) 733 42 17 37
E-MAIL info@adlego.se
REVENUE 15 MSEK in Sweden
EMPLOYEES 8
FOUNDED 2005
PUBLIC COMPANY No
PRINCIPAL OWNERS Urban Höglund

CTC CLINICAL TRIAL CONSULTANTS AB

We Translate Science into Treatment

CTC Clinical Trial Consultants AB is a full-service CRO with focus on clinical conduct.
Our mission is to facilitate clinical and translational research by providing our customers with cost-effective advice, conduct and reporting of clinical trials. We have four departments: Clinical Research Units, Clinical Operations, Pharmacovigilance and Biometrics, all supported by independent Quality Assurance management.

Trust our expertise in drug development, innovative techniques and translational research in the conduct of your early clinical program.

Anders Millerhovf, CEO

WEB www.ctc-ab.se
ADDRESS Dag Hammarskjölds väg 10B, 752 37 Uppsala, Sweden
PHONE +46 (0)18-30 33 00
E-MAIL info@ctc-ab.se
REVENUE 94 MSEK
EMPLOYEES 65+
FOUNDED 2011
PUBLIC COMPANY Public
CHAIRMAN Bengt Dahlström
PRINCIPAL OWNERS N/A

DB LAB A/S

GMP Contract Laboratory – more than a lab

DB Lab A/S is a Danish contract laboratory specialised in GMP analyses for the pharmaceutical industry and biotechnological industries, primarily in Denmark and Sweden. With more than 28 years of experience, we offer chemical, physical and microbiological GMP analyses on raw materials, intermediates, finished products, stability samples, process samples, cleaning validation samples and utensils. DB Lab is approved by the Danish Medicines Agency and has in addition been inspected by the FDA. We value quality, credibility, and the ongoing dialogue with our customers in order to provide the best service possible.
Our motto "more than a lab" stands for personal contact, open dialog, expectations alignment, keenness to establish the best solution for all parts and maintaining and enhancing our professional and quality competences.

We are pleased to experience the fact that our customers recommend us to their network.

Lisbeth Dahl Sørensen, CEO

WEB www.dblab.se
ADDRESS Lille Tornbjerg Vej 24, DK-5220 Odense, Denmark
PHONE +45 65 93 29 20
E-MAIL dblab@dblab.dk
EMPLOYEES 40
FOUNDED 1985
PUBLIC COMPANY Private

GALENICA

Your partner in pharmaceutical development

Galenica is a Swedish privately owned pharmaceutical company divided into three business units, contract development (CRO), contract manufacturing (CMO) and development of own pharmaceutical dermal products (PHARMA).
The CRO unit supports and guides our partners in their pharmaceutical development programs. We have expertise in pharmaceutical and analytical development as well as in production of clinical trial material for phase I up to phase III. In the CMO unit Galenica manufactures niched products for our customers to bring to the market. The PHARMA unit develops and launches Galenicas own pharmaceutical products to the market, utilizing our state-of-the-art expertise in drug formulation.

We had a successful 2021, looking forward to an expansion during 2022.

Ronnie Wallin, CEO

WEB www.galenica.se
ADDRESS Medeon Science Park
Per Albin Hanssons väg 41
205 12 Malmö, Sweden
PHONE +46 (0)40 32 10 95
E-MAIL info@galenica.se
REVENUE 150 MSEK
EMPLOYEES 80
FOUNDED 1999
PUBLIC COMPANY Private

LINK MEDICAL RESEARCH

Your LINK to Competence & Technology

LINK Medical is a full-service contract research organization (CRO) providing product development services for the pharmaceutical and medical device industries across Northern Europe. We offer a well-integrated local presence in the Nordics, UK, and Germany. Reaching from early phase development to post-marketing, we have over 180 employees providing expert guidance across every aspect of a project – all from ONE source. Our specialized oncology team thrives with complex oncology studies due to our broad multidisciplinary knowledge and long experience overcoming the associated challenges at every step. Our promise is to improve and accelerate your product development through transformative methods, active communication and optimal solutions.

As a strategic partner, we provide expert competence and technology to enable evidence-based decision-making that support the delivery of superior clinical outcomes.

Lena Lindeberg, Director, Commercial Operations

WEB www.LINKMedical.eu
ADDRESS Kungsängsvägen 19, SE-753 23 Uppsala, Sweden
PHONE +46 739 402 227
E-MAIL
lena.lindeberg@linkmedical.eu
Or contact https://linkmedical.eu/contact#contact-us
REVENUE about 225 Mill SEK
EMPLOYEES 180
FOUNDED 1995
PUBLIC COMPANY No
CHAIRMAN Jørgen Waaler
PRINCIPAL OWNERS
Ola Gudmundsen

SCANDINAVIAN CRO AB

Scandinavian CRO helps our clients to perform better clinical research

Scandinavian CRO, SCRO, performs complete studies or parts of projects within the field of clinical studies. Both within Pharma and MedTech. We are a full-service contract research organisation (CRO) that helps manage trial aspects such as feasibility studies, study design, medical writing, site selection, submission to authorities and ethics committees, monitoring, site management and pharmacovigilance, as well as study documentation, data management, statistics, and good clinical practice (GCP) training to ensure clinical studies comply with national and international regulations.

With passionate employees that truly enjoy what we do, Scandinavian CRO's vision is to support pharma and medtech companies, as well as academia, by helping them to translate their clinical research into health solutions that enable better future health solutions.

Ulrika Hammarström Lüllmaa, CEO and founder

WEB www.scro.se
ADDRESS Skolgatan 8, Box 150 27, 750 15 Uppsala, Sweden
PHONE +46 (0) 18 100 550
E-MAIL info@scro.se
REVENUE 31 000 000 SEK
EMPLOYEES 30
FOUNDED 2007
CHAIRMAN Ulf Boberg
PRINCIPAL OWNERS
Ulrika Hammarström Lüllmaa

TATAA BIOCENTER

Consistent quality is in our DNA

Recently recognized as one of the fastest growing tech companies in Sweden, TATAA is a leading provider of molecular analysis services, training courses, and high-quality reagents. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP), TATAA is perfectly positioned to support both the industry and academia with multiomics measurements. Our expertise is based on over two decades of experience in the nucleic acid analysis field, and is supported by a state-of-the-art sample management operation, automated workflows, and a digital laboratory ecosystem (LIMS, ELN).

We take pride in delivering rapid, robust and reproducible results that are submission-ready.

Mikael Kubista, CEO

WEB www.tataa.com
ADDRESS Sofierogatan 3A, 412 51 Göteborg
PHONE +46 31 761 57 00
E-MAIL info@tataa.com
REVENUE 100 MSEK
EMPLOYEES 50+
FOUNDED 2001
PUBLIC COMPANY No

ZELMIC AB

The CRO specialists in topical pharmacueticals

Zelmic were founded in 2002 and have developed several topical drugs and patented technologies for our customers. The company offers services in topical formulation development for small molecules, peptides, and proteins. The analytical capacities are R&D, GMP analysis, validation, and stability studies according to ICH. Zelmic can perform in-vitro release testing (IVRT) and In-vitro permeation testing (IVPT) with skin, nail, and mucous membrane according to new draft EMA guidance. We are now building a GMP facility for clinical manufacture to be completed during 2022.

Topical is all we do.

David Sagna, CEO

WEB www.zelmic.se
ADDRESS Sankt Lars väg 45 SE-222 70 Lund, Sweden
PHONE 46 46 16 12 40
E-MAIL david.sagna@zelmic.se or info@zelmic.se
FOUNDED 2002
PUBLIC COMPANY No
CHAIRMAN Jan Hellqvist

Company Name	Category	City	Website
A+ Science AB	CROs	Stockholm	a-plusscience.com
Adlego Biomedical AB	CROs	Uppsala	adlego.se
Aleris Medilab	CROs	Täby	alerisdiagnostics.se
Arandi Development AB	CROs	Stockholm	arandi.se
Bioperm AB	CROs	Lund	bioperm.se
BioVet AB	CROs	Sollentuna	biovet.se
Bragee Medect Clinical Trials	CROs	Stockholm	bragee.se
Ceffort AB	CROs	Lund	ceffort.com
Ceffort ControlSep AB	CROs	Lund	ceffort-controlsep.com
ClinTec International Ltd.	CROs	Göteborg	clintec.com
Consulting AB	CROs	Malmö	jcdc.se
CR Competence AB	CROs	Lund	colloidalresource.se
CTC Clinical Trial Consultants AB	CROs	Uppsala	ctc-ab.se
DB Lab A/S	CROs	Odense	dblab.se
EminTech	CROs	Lund	emintech.com
Galenica AB	CROs	Malmö	galenica.se
Harrison Clinical Research Sweden AB	CROs	Sollentuna	harrisoncinical.com
Herac AB	CROs	Huskvarna	herac.se
Hermelinen Forskning	CROs	Luleå	hermelinen.se
INC Research Sweden AB	CROs	Uppsala	incresearch.com
IRW Consulting AB	CROs	Danderyd	irwcro.com
Karolinska Trial Alliance	CROs	Stockholm	karolinskatrialalliance.se
KCR	CROs	Täby	kcrcro.com
KeytoLead AB	CROs	Södertälje	keytolead.se
Larix Sweden AB	CROs	Lund	larixcro.com
Late Phase Solutions Europe AB	CROs	Täby	latephasesolutions.com
LINK Medical Research	CROs	Kista	linkmedical.no
Medibiome AB	CROs	Mölndal	medibiome.com
Medpace Sweden AB	CROs	Stockholm	medpace.com
MicroMorph AB	CROs	Lund	micromorph.se
Mikro Kemi AB	CROs	Uppsala	mikrokemi.se
MVIC AB	CROs	Malmö	mvic.se
Nordic Health Economics	CROs	Göteborg	nordichealtheconomics.se
Nordic Regulatory Consultants	CROs	Vattholma	linkedin.com/in/ulfellerfelt
NordicBiocube	CROs	Lund	nordicbiocube.com
NORMA AB	CROs	Solna	norma-cro.com
Novandi Chemistry AB	CROs	Södertälje	novandi.se
OncoTargeting AB	CROs	Uppsala	oncotargeting.com
PCG Clinical Services AB	CROs	Uppsala	pharmaconsultinggroup.com
Pelago Bioscience AB	CROs	Stockholm	pelagobio.com
Pharm Assist Sweden AB	CROs	Uppsala	pharmassist.se
PharmaControl MQL AB	CROs	Uppsala	pharmacontrol.se
PPD Scandinavia AB	CROs	Stockholm	ppdi.com
PRA Health Sciences	CROs	Lund	prahs.com
Prionova	CROs	Helsingborg	prionova.com
Pronexus Analytical AB	CROs	Solna	pronexus.se
Quintiles AB	CROs	Uppsala	quintiles.com
Redoxis AB	CROs	Göteborg	redoxis.com
RegSmart Life Science AB	CROs	Uppsala	regsmart.se

CRO

Company Name	Category	City	Website
Scandinavian CRO AB	CROs	Uppsala	scro.se
Scandinavian Outcomes AB	CROs	Stockholm	scandinavianoutcomes.com
SOLVE Research & Consultancy	CROs	Lund	solveresearch.com
Statisticon AB	CROs	Uppsala	statisticon.se
Statistikkonsulterna	CROs	Göteborg	statistikkonsulterna.se
Syntagon AB	CROs	Södertälje	syntagon.com
TATAA Biocenter	CROs	Göteborg	tataa.com
TFS International AB	CROs	Lund	tfscro.com
Truly Translational Sweden AB	CROs	Lund	trulytranslational.com
UCR – Uppsala Clinical Research Center	CROs	Uppsala	ucr.uu.se
Vironova	CROs	Stockholm	vironova.com
Vironova Biosafety AB	CROs	Stockholm	vironovabiosafety.com
Zelmic AB	CROs	Lund	zelmic.se

LADULAAS CLINICAL TRIALS (LADULAAS AB)

Award winning site specialized in Clinical Trials

Our team collectively, has long experience in conducting clinical trials in phase II-IV.
We work together with most of the major pharmaceutical-, medical-, and CRO companies as well as cooperate with medical faculties all over the world. We are very successful in recruiting study participants, ensuring their safety and well-being and at the same time achieve ethical and scientific quality. We have participated in nearly 100 trials ranging from head to toe and where you can find the patients in the society, outpatients. We have been proud receivers of several awards for our work. We are easy to reach, situated in the center of Boras. It takes 20 minutes by car from Landvetter Airport (GOT). Within a radius of 70 km there are more than one million inhabitants. Send an e-mail to info@ladulaaskliniken.se and we will answer your feasibility in a promptly manner.

Try us for Trials!

Katarina Berndtsson Blom, CEO

WEB www.ladulaaskliniken.se
ADDRESS Skaraborgsvägen 35E, SE-506 30 Borås, Sweden
PHONE +46 (0) 33 13 13 31
E-MAIL Info@ladulaaskliniken.se
REVENUE 5-6 million SEK
EMPLOYEES 4-6
FOUNDED 2007
PUBLIC COMPANY No
CHAIRMAN
Katarina Berndtsson Blom
PRINCIPAL OWNERS
Private company

Company Name	Category	City	Website
Ladulaas Clinical Trials	Trial Sites	Boras/Gothenburg	ladulaaskliniken.se

INTELLECTUAL PROPERTY

Company Name	Category	City	Website
Advokatfirman Glimstedt	Intellectual Property	Lund	glimstedt.se
Advokatfirman Lindahl	Intellectual Property	Stockholm	lindahl.se
Aros Patent AB	Intellectual Property	Uppsala	arospatent.com
Awapatent AB	Intellectual Property	Malmö	awapatent.com
Bergenstråhle & Lindvall AB	Intellectual Property	Stockholm	bergenstrahle.se
Bird & Bird Advokatbyrå	Intellectual Property	Stockholm	twobirds.com
Bjerkéns patentbyrå KB	Intellectual Property	Stockholm	bjerken.se
Brann AB	Intellectual Property	Stockholm	brann.se
Groth & Co	Intellectual Property	Stockholm	groth.eu
Gärde Wesslau Advokatbyrå	Intellectual Property	Stockholm	garde.se
HØIBERG	Intellectual Property	Copenhagen K	hoiberg.com
Mannheimer Swartling Advokatbyrå	Intellectual Property	Stockholm	mannheimerswartling.se
Navia Law	Intellectual Property	Uppsala	navialaw.se
Novitas Patent AB	Intellectual Property	Stockholm	novitaspatent.com
OvaCell AB	Intellectual Property	Stockholm	ovacell.com
Petersens, Law firm af	Intellectual Property	Stockholm	afpetersens.se
Pierce Atwood LLP	Intellectual Property	Stockholm	pierceatwood.com
PRV Patent- och registreringsverket	Intellectual Property	Stockholm	prv.se
Sandart & Partners Advokatbyrå KB	Intellectual Property	Stockholm	sandart.se
Setterwalls Advokatbyrå i Stockholm AB	Intellectual Property	Stockholm	setterwalls.se
Ström & Gulliksson AB	Intellectual Property	Malmö	sg.se
Swea IP Law AB	Intellectual Property	Södertälje	swea-ip-law.se
Synergon AB - Göteborg	Intellectual Property	Göteborg	synergon.se
Synergon AB - Stockholm	Intellectual Property	Stockholm	synergon.se
Valea AB	Intellectual Property	Göteborg	valea.se
Zacco	Intellectual Property	Stockholm	zacco.co

OPTIMIZE COURIER (SWEDEN) AB

Worldwide time & temperature specialist

Optimize Courier is a global specialty and GDP compliant courier company dedicated to the worldwide coordination & transportation of biological, pharmaceutical, time critical and cold chain logistics. Operating 24 hours a day, 7 days a week with decades of experience behind us, we promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us.

"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us.

Jan Karlsson

optimize courier

ADDRESS Box 108, Maskingatan 17c, Arlanda Stad, 190 46 Stockholm-Arlanda TEL: 08-594 501 10
E-MAIL ops@optimizecourier.se
REVENUE N/A
EMPLOYEES 4
FOUNDED 2007
PUBLIC COMPANY No
CHAIRMAN Jan Karlson
PRINCIPAL OWNER Jan Karlsson

SHIMADZU

The full range of analytical instrumentation solutions

Shimadzu, one of the world leaders in analytical instrumentation, has recently opened its own branch office in Sweden. The office hosts administration space as well as a demonstration lab and seminar rooms. In the demo lab, latest solutions and products will be highlighted. In this environment, both existing and potential customers can get first impressions of the systems regarding size and footprint. They can experience the systems running and test them in operation. The office markets Shimadzu's full range of analytical instrumentation solutions covering chromatography, mass spectrometry, TOC (sum parameter) and spectroscopy. Depending on the analytical needs, Shimadzu offers standard or customized solutions to support individual tasks in routine applications and method development challenges.

"With our own branch office, we intend to fully serve the needs of Swedish companies and industries.

Lage Thaning, Managing Director

SHIMADZU
Excellence in Science

WEB www.shimadzu.se
ADDRESS Shimadzu Filial Sverige Finlandsgatan 40, 164 74 Kista, Sweden
PHONE +46 (0)8-171770
E-MAIL info@shimadzu.se
REVENUE n/a
EMPLOYEES 15
FOUNDED 2019
PUBLIC COMPANY No
MANAGING DIRECTOR Lage Thaning

VWR INTERNATIONAL AB

From breakthrough discovery to agile delivery of innovative products and services

As the delivery channel of Avantor®, a Fortune 500 company, VWR provides access to mission-critical product and service solutions across life sciences and other regulated industries, including: pharmaceutical, biotechnology, industrial, education, government, healthcare and advanced technologies. We offer an integrated, seamless purchasing experience that is optimized for the way our customers do business and supported by a strong global distribution network. Our global e-commerce platform provides an easy, convenient access to an extensive portfolio, including our own brands, as well as those from thousands of other manufacturers. With a dedicated team of more than 12,000 associates, Avantor is a trusted global partner to customers and suppliers in the life sciences and advanced technologies & applied materials industries.

"Our mission: We set science in motion to create a better world.

Carl Henrik Edfors

avantor™
delivered by VWR™

WEB se.vwr.com
ADDRESS Fagerstagatan 18A 163 53 Spånga
PHONE +46 8 621 34 20
E-MAIL kundservice.se@vwr.com
REVENUE 878 MSEK
EMPLOYEES 169
FOUNDED 1906
PUBLIC COMPANY No
CHAIRMAN Bernd Goell
PRINCIPAL OWNERS Vail Holdco Corp.

SUPPLIERS (DISTRIBUTORS)

Company Name	Category	City	Website
AddLife AB	Suppliers (Distributors)	Stockholm	add.life
ADDvise Lab Solutions AB	Suppliers (Distributors)	Bromma	addvise.se
ADDvise Tillquist AB	Suppliers (Distributors)	Bromma	tillquist.se
A-Filter AB	Suppliers (Distributors)	Västra Frölunda	a-filter.se
AgnTho´s AB	Suppliers (Distributors)	Lidingö	agnthos.se
AH Diagnostics AB	Suppliers (Distributors)	Solna	ahdiagnostics.se
Beckman Coulter AB	Suppliers (Distributors)	Bromma	beckman.com
BergmanLabora AB	Suppliers (Distributors)	Danderyd	bergmanlabora.se
BioNordika Sweden AB	Suppliers (Distributors)	Stockholm	bionordika.se
Biotech-IgG A/S	Suppliers (Distributors)	København Ø	biotech-igg.com
Biox AB	Suppliers (Distributors)	Göteborg	bioxab.se
Brookhaven Instruments AB	Suppliers (Distributors)	Älvsjö	brookhaven.se
Bruker AXS Nordic AB	Suppliers (Distributors)	Solna	bruker-axs.se
Bruker Daltonics Scandinavia AB	Suppliers (Distributors)	Solna	bruker.se
Carl Zeiss AB	Suppliers (Distributors)	Stockholm	zeiss.se
Chemical Instruments AB	Suppliers (Distributors)	Sollentuna	ciab.se
Colly Flowtech AB	Suppliers (Distributors)	Kista	colly.se
Crelab Instruments AB	Suppliers (Distributors)	Billdal	crelab.se
Fisher Scientific	Suppliers (Distributors)	Västra Frölunda	thermofisher.com
Gammadata Instrument AB	Suppliers (Distributors)	Uppsala	gammadatainstrument.se
Genano Luftreningsteknik	Suppliers (Distributors)	Landskrona	genano.se
HAB Nicolai Johannsen	Suppliers (Distributors)	Lidingö	habnj.se
Hettich Labinstrument AB	Suppliers (Distributors)	Sollentuna	hettichlabinstrument.se
Ken-En-Tec Nordic	Suppliers (Distributors)	Uppsala	kem-en-tec-nordic.com
Kompauto Nordic AB	Suppliers (Distributors)	Ludvika	kompauto.com
Kovalent AB	Suppliers (Distributors)	Västra Frölunda	kovalent.se
L.A.B. Sweden AB	Suppliers (Distributors)	Farsta	lab.se
Labex Instrument AB	Suppliers (Distributors)	Helsingborg	labexinstrument.com
Labinett AB	Suppliers (Distributors)	Göteborg	labinettlab.se
Labinova AB	Suppliers (Distributors)	Upplands Väsby	labinova.se
LabRum AB	Suppliers (Distributors)	Solna	labrum.se
LabRum Klimat AB	Suppliers (Distributors)	Solna / Stockholm	labrum.se
LabTeamet - Labteam Scandinavia AB	Suppliers (Distributors)	Helsingborg	labteamet.com
LabVision AB	Suppliers (Distributors)	Värmdö	labvision.se
LECO Corporation Svenska AB	Suppliers (Distributors)	Upplands Väsby	leco-europe.com
LGC Standards AB	Suppliers (Distributors)	Borås	lgcpromochem.com
MediQip AB	Suppliers (Distributors)	Huddinge	mediqip.se
Metix AB	Suppliers (Distributors)	Alingsås	metix.se
Miclev AB	Suppliers (Distributors)	Limhamn/Malmö	miclev.se
Milmedtek AB	Suppliers (Distributors)	Nättraby	milmedtek.se
Molek AB	Suppliers (Distributors)	Årsta	molek.se
Ninolab AB	Suppliers (Distributors)	Upplands Väsby	ninolab.se
Noax Lab AB	Suppliers (Distributors)	Kungsängen	noaxlab.se
Nordic Biolabs AB	Suppliers (Distributors)	Täby	nordicbiolabs.se
Nordic BioSite AB	Suppliers (Distributors)	Täby	nordicbiosite.com
Nordic Diagnostica AB	Suppliers (Distributors)	Billdal	nordicdiagnostica.com
Nordic Pack AB	Suppliers (Distributors)	Nykvarn	nordicpack.com
Novakemi AB	Suppliers (Distributors)	Handen	novakemi.se
Oleinitec AB	Suppliers (Distributors)	Lidingö	oleinitec.se
Optimize Courier (Sweden) AB	Suppliers (Distributors)	Arlandastad	optimizecourier.com
Oxoid AB, Thermo Fisher Scientific	Suppliers (Distributors)	Malmö	thermofisher.com
Pharmapack Agenturer AB	Suppliers (Distributors)	Sollentuna	pharmapack.se
Saveen & Werner AB	Suppliers (Distributors)	Malmö	swab.se

SUPPLIERS (DISTRIBUTORS)

Company Name	Category	City	Website
Scandinavian Medical Service	Suppliers (Distributors)	Helsingborg	sms-gruppen.dk
Scantec Nordic AB	Suppliers (Distributors)	Partille	scantecnordic.se
Science Imaging Scandinavia AB	Suppliers (Distributors)	Nacka	scienceimaging.se
Shimadzu	Suppliers (Distributors)	Kista	shimadzu.se
Skafte MedLab AB	Suppliers (Distributors)	Onsala	skafte.se
Skandinaviska Genetec AB	Suppliers (Distributors)	Västra Frölunda	genetec.se
Sorbent AB	Suppliers (Distributors)	Västra Frölunda	sorbent.se
Spectral Solutions AB	Suppliers (Distributors)	Lidingö	spectral.se
Teamator AB	Suppliers (Distributors)	Helsingborg	teamator.com
Techtum Lab AB	Suppliers (Distributors)	Umeå	techtum.se
Th. Geyer Sverige AB	Suppliers (Distributors)	Segeltorp	thgeyer.se
Thurne Teknik AB	Suppliers (Distributors)	Stockholm	thurne.se
Waters AB	Suppliers (Distributors)	Sollentuna	waters.com
Wirth emballage	Suppliers (Distributors)	Åkersberga	wirth.se
VWR International AB	Suppliers (Distributors)	Stockholm	se.vwr.com

SUPPLIERS (MANUFACTURERS)

Company Name	Category	City	Website
3H Biomedical AB	Suppliers (Manufactures)	Uppsala	3hbiomedical.com
AGA Gas AB	Suppliers (Manufactures)	Lidingö	aga.se
Agilent Technologies AB	Suppliers (Manufactures)	Kista	non.agilent.com
AgriSera AB	Suppliers (Manufactures)	Vännäs	agrisera.com
Alfa Laval	Suppliers (Manufactures)	Lund	alfalaval.com/biopharm
AlphaHelix Molecular Diagnostics AB	Suppliers (Manufactures)	Uppsala	alphahelix.com
Anton Paar Nordic AB	Suppliers (Manufactures)	Malmö	anton-paar.com
Atlas Antibodies AB	Suppliers (Manufactures)	Stockholm	atlasantibodies.com
Attana AB	Suppliers (Manufactures)	Stockholm	attana.com
BD Biosciences	Suppliers (Manufactures)	Stockholm	bdbeurope.com
Belach Bioteknik AB	Suppliers (Manufactures)	Skogås	belach.se
Bio-Rad Laboratories AB	Suppliers (Manufactures)	Sundbyberg	bio-rad.com
Bio-Works Sweden AB	Suppliers (Manufactures)	Bromma	bio-works.net
BioLamina	Suppliers (Manufactures)	Sundbyberg	biolamina.com
BiolinScientific	Suppliers (Manufactures)	Västra Frölunda	biolinscientific.com
BioSafe AB	Suppliers (Manufactures)	Hallstahammar	biosafe.eu
Biotage AB	Suppliers (Manufactures)	Uppsala	biotage.com
Biotech AB	Suppliers (Manufactures)	Onsala	biotech.se
BioThema AB	Suppliers (Manufactures)	Handen	biothema.com
Birka BioStorage AB	Suppliers (Manufactures)	Lund	birkabiostorage.com
Bürkert-Contromatic AB	Suppliers (Manufactures)	Malmö	burkert.se
Cellectricon AB	Suppliers (Manufactures)	Göteborg	cellectricon.com
Christian Berner AB	Suppliers (Manufactures)	Mölnlycke	christianberner.com
CMA Microdialysis AB	Suppliers (Manufactures)	Kista	microdialysis.se
Cobolt AB	Suppliers (Manufactures)	Solna	cobolt.se
CyberGene AB	Suppliers (Manufactures)	Solna	cybergene.se
Cytvia	Suppliers (Manufactures)	Uppsala	cytiva.com
Deltatec Pharma	Suppliers (Manufactures)	Trollhättan	deltatec.se
DuPont Chemoswed	Suppliers (Manufactures)	Malmö	dupont.com
European Institute of Science AB	Suppliers (Manufactures)	Lund	euris.org
Fagerström Pharma Systems AB	Suppliers (Manufactures)	Helsingborg	fagerstrom.se
Fluicell AB	Suppliers (Manufactures)	Gothenburg	fluicell.com
Genovis AB	Suppliers (Manufactures)	Lund	genovis.com
Getinge AB	Suppliers (Manufactures)	Getinge	getinge.com
Gradientech AB	Suppliers (Manufactures)	Uppsala	gradientech.se
Gyros AB	Suppliers (Manufactures)	Uppsala	gyros.com
ICU Scandinavia AB	Suppliers (Manufactures)	Täby	icuscandinavia.com
Implementa Hebe, AB	Suppliers (Manufactures)	Lund	implementa.se
Infogosoft	Suppliers (Manufactures)		infogosoft.com
Innovagen AB	Suppliers (Manufactures)	Lund	innovagen.se
Inovata AB	Suppliers (Manufactures)	Bromma	inovata.se
Krüger Akvapur AB	Suppliers (Manufactures)	Solna	kruger.se
KNF Neuberger GmbH	Suppliers (Manufactures)	Freiburg	knf.com
Lab Automation Nordic AB	Suppliers (Manufactures)	Nyköping	labautomation.nu
Lab on a Bead AB	Suppliers (Manufactures)	Uppsala	labonabead.se
LabRobot Products AB	Suppliers (Manufactures)	Stenungsund	labrobot.com
Legosan AB	Suppliers (Manufactures)	Kumla	legosan.se
Leica Microsystems AB	Suppliers (Manufactures)	Kista	leica-microsystems.com

SUPPLIERS (MANUFACTURERS)

Company Name	Category	City	Website
Mabtech AB	Suppliers (Manufactures)	Nacka Strand	mabtech.com
MacoPharma Nordic AB	Suppliers (Manufactures)	Helsingborg	macopharma.se
Magellan Instruments AB	Suppliers (Manufactures)	Stockholm	magellaninstruments.com
Malvern Instruments Nordic AB	Suppliers (Manufactures)	Uppsala	malvern.com
Masimo Sweden AB	Suppliers (Manufactures)	Danderyd	masimo.com
Mercodia AB	Suppliers (Manufactures)	Uppsala	mercodia.com
Mettler-Toledo AB	Suppliers (Manufactures)	Stockholm	mt.com
Mglas Scandinavia AB	Suppliers (Manufactures)	Sollentuna	mglas.se
Microbiotech/se AB	Suppliers (Manufactures)	Stockholm	microbiotech.se
Millipore AB	Suppliers (Manufactures)	Solna	millipore.com
Miltenyi Biotec Norden AB	Suppliers (Manufactures)	Lund	miltenyibiotec.com
MIP Technologies AB	Suppliers (Manufactures)	Lund	biotage.se
Nanoxis AB	Suppliers (Manufactures)	Göteborg	nanoxis.com
Nordiag AB	Suppliers (Manufactures)	Hägersten	nordiag.com
Novaferm AB	Suppliers (Manufactures)	Bunkeflostrand	novaferm.se
Novozymes Biopharma Sweden AB	Suppliers (Manufactures)	Lund	novozymes.com
Obducat AB	Suppliers (Manufactures)	Malmö	obducat.com
Octanorm Nordic AB	Suppliers (Manufactures)	Spånga	octanorm.se
Olink AB	Suppliers (Manufactures)	Uppsala	olink.com
Parker Hannifin AB	Suppliers (Manufactures)	Spånga	parker.com/lifesciences/rg
PartnerTech AB	Suppliers (Manufactures)	Malmö	partnertech.com
Percell Biolytica AB	Suppliers (Manufactures)	Åstorp	percell.se
PerkinElmer Sverige AB	Suppliers (Manufactures)	Upplands Väsby	perkinelmer.com
Picovitro AB	Suppliers (Manufactures)	Stockholm	picovitro.com
PlantVision AB	Suppliers (Manufactures)	Kista	plantvision.se
PolyPeptide Laboratories AB	Suppliers (Manufactures)	Limhamn	polypeptide.com
Promega Biotech AB	Suppliers (Manufactures)	Nacka	promega.com/se
Q-Med AB	Suppliers (Manufactures)	Uppsala	q-med.com
Qiagen AB	Suppliers (Manufactures)	Sollentuna	qiagen.com
Ridgeview Instruments AB	Suppliers (Manufactures)	Uppsala	ridgeviewinstruments.com
RSA Biomedical AB	Suppliers (Manufactures)	Umeå	rsabiomedical.se
Sarstedt AB	Suppliers (Manufactures)	Helsingborg	sarstedt.com
Scandinavian Gene Synthesis AB	Suppliers (Manufactures)	Köping	sgsdna.com
Sigma-Aldrich Sweden AB	Suppliers (Manufactures)	Stockholm	sigma-aldrich.com
SMC Pneumatics Sweden AB	Suppliers (Manufactures)	Huddinge	smc.nu
Stegia AB	Suppliers (Manufactures)	Västerås	stegia.se
Symcel Sverige AB	Suppliers (Manufactures)	Kista	symcel.se
Sympatec Nordic	Suppliers (Manufactures)	Vimmerby	sympatec.com
TdB Consultancy AB	Suppliers (Manufactures)	Uppsala	tdbcons.se
Tecan Nordic AB	Suppliers (Manufactures)	Mölndal	tecan.com
Thermo Fisher Scientific	Suppliers (Manufactures)	Kungens Kurva	thermofisher.com
Trelleborg Sealing Solutions Sweden AB	Suppliers (Manufactures)	Jönköping	tss.trelleborg.com/se
Vaisala Oyj	Suppliers (Manufactures)	Upplands Väsby	vaisala.com
W-M Alitea AB	Suppliers (Manufactures)	Stockholm	watson-marlow.se
YO Proteins AB	Suppliers (Manufactures)	Huddinge	yoproteins.com

INDEX

INDEX

Company Name	Category	City	Website
AnoxKaldnes Global AB	Business Devel/Service	Lund	anoxkaldnes.com
Antaros Medical AB	Business Devel/Service	Mölndal	antarosmedical.com
Anton Paar Nordic AB	Suppliers (Manufactures)	Malmö	anton-paar.com
APL - Apotek Produktion & Laboratorier AB	CMOs	Kungens Kurva, Stockholm	apl.se
Aprea AB	Biotech	Solna	aprea.com
Aprovix AB	Medtech	Uppsala	aprovix.se
Arandi Development AB	CROs	Stockholm	arandi.se
AroCell AB	Medtech	Uppsala	arocell.com
Aros Patent AB	Intellectual Property	Uppsala	arospatent.com
Arthur D. Little AB	Business Devel/Service	Stockholm	adlittle.com
Asarina Pharma AB	Biotech	Solna	asarinapharma.com
Ashfield Nordic AB (formerly known as Pharmexx Nordic AB)	Business Devel/Service	Stockholm	ashfieldhealthcare.com
Aspira Medical AB	Medtech	Borlänge	aspira.se
AssuransSelector AB	Business Devel/Service	Helsingborg	assuransselector.se
AstaReal AB	Biotech	Gustavsberg	astareal.se
AstraTech AB	Medtech	Mölndal	astratech.com
AstraZeneca AB	Pharma	Södertälje	astrazeneca.se
Athera Biotechnologies AB (publ)	Biotech	Solna	athera.se
Atlas Antibodies AB	Suppliers (Manufactures	Stockholm	atlasantibodies.com
Attana AB	Suppliers (Manufactures)	Stockholm	attana.com
Aurena Laboratories AB	Biotech	Karlstad	aurenalabs.com
Awapatent AB	Intellectual Property	Malmö	awapatent.com
Axcentua Pharmaceuticals AB	Biotech	Huddinge	axcentua.com
B. Braun Medical AB	Medtech	Danderyd	bbraun.com
Baxter Medical AB - BioScience Division	Medtech	Kista	baxter.se
BD Biosciences	Suppliers (Manufactures)	Stockholm	bdbeurope.com
Beactica AB	Biotech	Uppsala	beactica.com
Beckman Coulter AB	Suppliers (Distributors)	Bromma	beckman.com
Belach Bioteknik AB	Suppliers (Manufactures)	Skogås	belach.se
Berendsen Textil Service AB	Business Devel/Service	Nyköping	berendsen.se
Bergenstråhle & Lindvall AB	Intellectual Property	Stockholm	bergenstrahle.se
BergmanLabora AB	Suppliers (Distributors)	Danderyd	bergmanlabora.se
Betagenon AB	Biotech	Umeå	betagenon.com
Binab Bio-Innovation AB	Biotech	Helsingborg	binab.se
Bio-Rad Laboratories AB	Suppliers (Manufactures	Sundbyberg	bio-rad.com
Bio-Works Sweden AB	Suppliers (Manufactures)	Bromma	bio-works.net
BioAgri AB	Biotech	Uppsala	bioagri.se
BioArctic Neuroscience AB	Biotech	Stockholm	bioarctic.se
Biobact AB	Biotech	Luleå	biobact.se
BioChromix AB	Medtech	Stockholm	biochromix.com
BioChromix Pharma AB	Biotech	Stockholm	swedishlifesciences.se/x
BioGaia AB	Biotech	Stockholm	biogaia.se
BiogenIdec Sweden AB	Biotech	Upplands Väsby	biogenidec.com
Bioglan AB	CMOs	Malmö	bioglan.se
Biognos AB	Biotech	Göteborg	biognos.com
BioInvent International AB	Biotech	Lund	bioinvent.com
BioLamina	Suppliers (Manufactures)	Sundbyberg	biolamina.com
BiolinScientific	Suppliers (Manufactures)	Västra Frölunda	biolinscientific.com
BioMedLit	Business Devel/Service	Järfälla	biomedlit.com
bioMérieux Sweden AB	Medtech	Askim	biomerieux.com

INDEX

INDEX

Company Name	Category	City	Website
Cellink AB	Biotech	Göteborg	cellink.com
Cellwell	Medtech	Åkersberga	cellwell.se
Cenova AB Innovation & Production	Medtech	Mjölby	cenova.se
Cepheid AB	Medtech	Bromma	affigene.com
Cerner	Medtech	Stockholm	cerner.com
Cewatech AB	Medtech	Göteborg	cewatech.se
Chemical Instruments AB	Suppliers (Distributors)	Sollentuna	ciab.se
Chemilia AB	Biotech	Huddinge	chemilia.com
Chemnotia AB	Business Devel/Service	Bromma	chemnotia.com
Christian Berner AB	Suppliers (Manufactures)	Mölnlycke	christianberner.com
ChronTech Pharma AB		Huddinge	chrontech.se
Chubb Insurance Company of Europe S.A.	Business Devel/Service	Stockholm	chubb.com/international/se
CITEC	Business Devel/Service	Karlstad	citec.com
Clean Room Control AB	Business Devel/Service	Uppsala	cr-control.se
Clinical Gene Networks	BioIT	Stockholm	clinicalgenenetworks.com
ClinStorage AB	Business Devel/Service	Solna, Sweden	clinstorage.se
ClinTec International Ltd.	CROs	Göteborg	clintec.com
CMA Microdialysis AB	Suppliers (Manufactures)	Kista	microdialysis.se
CMC Contrast AB	Biotech	Malmö	cmccontrast.com
Cobolt AB	Suppliers (Manufactures)	Solna	cobolt.se
Cobra Biologics	CMOs	Matfors	cobrabio.com
Colly Flowtech AB	Suppliers (Distributors)	Kista	colly.se
Coloplast A/S Humlebaek	Medtech	Danmark	coloplast.se
Comair Professor Hans Wiksell AB	Medtech	Stockholm	comair.se
Compass Rekrytering & Utveckling AB	Business Devel/Service	Stockholm	compass.se
Compumine AB	BioIT	Uppsala	compumine.com
Comsol AB	BioIT	Stockholm	comsol.com
Conlega Biobusiness Development and Management HB	Business Devel/Service	Uppsala	conlega.com
Contur Software AB	BioIT	Stockholm	contur.com
Copenhagen Bio Science Park	Business Devel/Service	Copenhagen N	cobis.dk
Corline Systems AB	Medtech	Uppsala	corline.com
CR Competence AB	CROs	Lund	colloidalresource.se
CR Development	Medtech	Lund	colloidalresource.se
Crelab Instruments AB	Suppliers (Distributors)	Billdal	crelab.se
CropTailor AB	Biotech	Göteborg	croptailor.com
Crucell Sweden AB	Biotech	Stockholm	crucell.se
CTC Clinical Trial Consultants AB	CROs	Uppsala	ctc-ab.se
Cubist IT AB	Medtech	Stockholm	cubist.eu
CyberGene AB	Suppliers (Manufactures)	Solna	cybergene.se
Cytvia	Suppliers (Manufactures)	Uppsala	cytiva.com
Damn Good Agency	Business Devel/Service	Stockholm	dga.se
DanPET	Biotech	Malmö	danpet.eu
DB Lab A/S	CROs	Odense	dblab.se
Deltatec Pharma	Suppliers (Manufactures)	Trollhättan	deltatec.se
Demetech AB	Medtech	Täby	demetech.com
Devex Mekatronik AB	Business Devel/Service	Skarpnäck, Stockholm	devexmekatronik.se
Devex ProPart AB	Business Devel/Service	Skarpnäck, Stockholm	devex.se
Devyser AB	Medtech	Stockholm	devyser.com
Dfind Science & Engineering AB	Business Devel/Service	Stockholm	dfind.se/science-engineering
DHL Express Nordic	Business Devel/Service	Stockholm	dhl.com

INDEX

INDEX

INDEX

INDEX

Company Name	Category	City	Website
Legosan AB	Suppliers (Manufactures)	Kumla	legosan.se
Leica Microsystems AB	Suppliers (Manufactures)	Kista	leica-microsystems.com
LGC Standards AB	Suppliers (Distributors)	Borås	lgcpromochem.com
LIDDS AB	Biotech	Helsingborg	liddspharma.com
Lidingö Elektriska	Business Devel/Service	Lidingö	lidingoelektriska.se
LifeAssays AB	Medtech	Lund	lifeassays.com
Likvor AB	Medtech	Umeå	likvor.com
LINK Medical Research	CROs	Kista	linkmedical.no
LinkoCare Life Sciences AB	Medtech	Linköping	linkocarelife.com
Lipum AB	Biotech	Umeå	lipum.se
Logos - global language service provider to the life sciences industry	Business Devel/Service	Ystad	logos.net
LucyJRobertshaw	Business Devel/Service	Hölö	lucyjrobertshaw.com
Mabtech AB	Suppliers (Manufactures)	Nacka Strand	mabtech.com
MacoPharma Nordic AB	Suppliers (Manufactures)	Helsingborg	macopharma.se
Magellan Instruments AB	Suppliers (Manufactures)	Stockholm	magellaninstruments.com
Magle AB	Biotech	Lund	magle.se
Malvern Instruments Nordic AB	Suppliers (Manufactures)	Uppsala	malvern.com
Mandalon Technologies AB	Business Devel/Service	Linköping	mandalon.se
Mandly Search & Selection	Business Devel/Service	Stockholm	mandly.se
Mannheimer Swartling Advokatbyrå	Intellectual Property	Stockholm	mannheimerswartling.se
Marken Ltd.	Business Devel/Service	Stockholm-Arlanda	marken.com
Masimo Sweden AB	Suppliers (Manufactures)	Danderyd	masimo.com
MD Medical Writing & Translations	Business Devel/Service	Hammenhög	mariadalby.com
Meda AB	Biotech	Solna	meda.se
Medeca Pharma AB	Pharma	Uppsala	medeca.se
Medeon AB	Business Devel/Service	Malmö	medeon.se
MedHelp	Medtech	Stockholm	medhelp.se
Medibiome AB	CROs	Mölndal	medibiome.com
Medic Valley Rekrytering AB	Business Devel/Service	Tomelilla	medicvalley.se
Medicago AB	CMOs	Uppsala	medicago.se
Medical Lead Nordic AB	Business Devel/Service	Stockholm	medicallead.se
Medicon Valley Alliance	Business Devel/Service	Copenhagen	mva.org
Medicon Village	Business Devel/Service	Lund	mediconvillage.se
MedicWave AB	BioIT	Halmstad	medicwave.com
Medicvent AB	Medtech	Umeå	medicvent.se
MediGelium AB	Business Devel/Service	Stockholm	sciencepark.ki.se/node/125
Mediplast AB	Medtech	Malmö	mediplast.com
MediQip AB	Suppliers (Distributors)	Huddinge	mediqip.se
MediRox AB	Medtech	Nyköping	medirox.se
Medivir AB	Pharma	Stockholm	medivir.se
Medmind	Business Devel/Service	Stockholm	medmind.se
Medos AB	Business Devel/Service	Linköping	medos.se
Medpace Sweden AB	CROs	Stockholm	medpace.com
MEDWIND	Medtech	Kungsbacka	medwind.se
Mentice AB	Medtech	Göteborg	mentice.com
Merck AB	Pharma	Solna	merck.se
Mercodia AB	Suppliers (Manufactures)	Uppsala	mercodia.com
Merrill Brink International	Business Devel/Service	Torslanda	merrillbrink.com
MetaSafe AB	Business Devel/Service	Södertälje	metasafe.se
Metix AB	Suppliers (Distributors)	Alingsås	metix.se
Mettler-Toledo AB	Suppliers (Manufactures)	Stockholm	mt.com

INDEX

INDEX

INDEX

INDEX

Company Name	Category	City	Website
QureTech Bio AB	Biotech	Umeå	quretech.com
Raise-In AB	Business Devel/Service	Älvsjö	raise-in.se
Ramidus AB	Business Devel/Service	Lund	ramidus.se
Recipharm	Pharma	Stockholm	recipharm.com
Red Glead Discovery AB	Biotech	Lund	redglead.com
Redoxis AB	CROs	Göteborg	redoxis.com
Redsense Medical	Medtech	Halmstad	redsensemedical.com
Redwood Pharma AB	Pharma	Stockholm	redwoodpharma.se
RegSafe - Regulatory Safety Sciences	Business Devel/Service	Stocksund	regsafe.se
RegSmart Life Science AB	CROs	Uppsala	regsmart.se
Respiratorius AB	Biotech	Lund	respiratorius.com
Ridgeview Instruments AB	Suppliers (Manufactures)	Uppsala	ridgeviewinstruments.com
Roche	Pharma	Stockholm	roche.se
Roche Diagnostics Scandinavia AB	Medtech	Bromma	roche.se
Rossix AB	Medtech	Mölndal	rossix.com
RSA Biomedical AB	Suppliers (Manufactures)	Umeå	rsabiomedical.se
SAGA Diagnostics AB	Medtech	Lund	sagadiagnostics.com
Sahlgrenska Science Park	Business Devel/Service	Göteborg	sahlgrenskasciencepark.se
Sandart & Partners Advokatbyrå KB	Intellectual Property	Stockholm	sandart.se
Sanofi	Pharma	Bromma	sanofi.se
SARomics Biostructures AB	Biotech	Lund	saromics.com
Sarstedt AB	Suppliers (Manufactures)	Helsingborg	sarstedt.com
Saveen & Werner AB	Suppliers (Distributors)	Malmö	swab.se
Scalae AB	Medtech	Dalby	scalae.se
ScanBi Diagnostics AB	Biotech	Alnarp	scanbidiagnostics.com
Scandinavian CRO AB	CROs	Uppsala	scro.se
Scandinavian Development Services	Business Devel/Service	Danderyd	scanddev.se
Scandinavian Gene Synthesis AB	Suppliers (Manufactures)	Köping	sgsdna.com
Scandinavian Medical Service	Suppliers (Distributors)	Helsingborg	sms-gruppen.dk
Scandinavian Outcomes AB	CROs	Stockholm	scandinavianoutcomes.com
Scandinavian Regulatory Services AB	Business Devel/Service	Danderyd	srs.se
Scantec Nordic AB	Suppliers (Distributors)	Partille	scantecnordic.se
SciBase AB	Medtech	Stockholm	scibase.se
Science Imaging Scandinavia AB	Suppliers (Distributors)	Nacka	scienceimaging.se
Scientific Solutions Scandinavia AB	Business Devel/Service	Stockholm	scientificsolutions.se
Scientific Work	Business Devel/Service	Nacka	scientificwork.se
Semcon	Business Devel/Service	Göteborg	semcon.com
Senator Medical AB	Business Devel/Service	Upplands-Bro	senatormedical.se
SentoClone International AB	Biotech	Stockholm	sentoclone.com
Senzime AB	Medtech	Uppsala	senzime.com
Serviceföretaget PIMA AB	Business Devel/Service	Södertälje	pima.se
Setterwalls Advokatbyrå i Stockholm AB	Intellectual Property	Stockholm	setterwalls.se
Shimadzu	Suppliers (Distributors)	Kista	shimadzu.se
SHL Group AB	Medtech	Nacka Strand	shl-group.net
SHL Technologies	Medtech	Nacka Strand	shl-group.com
Siemens Healthcare Diagnostics AB	Medtech	Upplands Väsby	siemens.com/diagnostics
Sigma-Aldrich Sweden AB	Suppliers (Manufactures)	Stockholm	sigma-aldrich.com
Silentia	Medtech	Falkenberg	silentia.se
SIS, Swedish Standards Institute	Business Devel/Service	Stockholm	sis.se
Skafte MedLab AB	Suppliers (Distributors)	Onsala	skafte.se
Skandinaviska Genetec AB	Suppliers (Distributors)	Västra Frölunda	genetec.se

INDEX

INDEX

Leading in news and events

Our magazine Life Science Sweden is the leading and most well known life science magazine in the Nordics. We cover research, science and the development of medical treatments, from idea all the way through preclinical and clinical stages to society and the patient. The printed editon of Life Science Sweden is published four times each year and lifesciencesweden.se is updated several times every day with the most current and relevant news. Our newsletters are sent to 15.400 recipients four times a week. Every year we organize 6-7 international partnering-events. Our unique communication platform includes:

1. **6 annual international partnering-events**
2. **Magazine Life Science Sweden (3 issues in Swedish/year + 1 international issue in English/year)**
3. **The Swedish Life Science Industry Guide**
4. **4 Newsletters/week to 15.400 recipients**
5. **News portal lifesciencesweden.se**
6. **Podcast "Life Science-podden" 4 times/year**
7. **Membership**

Editor in Chief **Samuel Lagercrantz**
+46 (0)79-337 19 60, samuel.lagercrantz@nordiskemedier.se

These are the people we reach: Procurers, politicians at the regional level, drug committees, business management in health care, university and university researchers/biomedical scientists, lab managers, biomedical analysts, chemists/chemical engineers, VC's/investment managers, decision makers in the biotech, pharmaceutical, chemical and nanotech industry. The industries we reach include recruitment, advertising, sales, contract manufacturers, patents and regulatory, market access and legal advice.

Our events 2022
All of our events are annual international partnering meetings with pre-bookable face to face meetings. The events are covered by the media.

Lab & Diagnostics of the Future
April 7th, Stockholm. **labdiagnostics.eu**

New Updates in Drug Formulation & Bioavailability
September 6th, Copenhagen
formulationsbioavailability.com

The Future of Swedish & Danish Life Science
September 7th, Lund. **swedishdanishlifescience.se**

Bioscience – Research & Diagnostics through Innovative Technologies
November 8th, Stockholm. **bioscienceevent.com**

Pharma Outsourcing – Find the right partner
December 1st, Stockholm. **pharmaoutsourcing.eu**

New Horizons in Biologics & Bioprocessing
December 15th, Stockholm. **bioprocessing.se**

Business Development Manager/Founder Events/ Event Managing Director
Maria Eriksson
+46 (0)70-874 18 34
maria.eriksson@nordiskemedier.se

Publishing schedule 2022

ISSUE	PUBLISHING DATE	MATERIAL DATE	TRADE FAIR*/SPECIAL THEME
1	Feb 28th	Feb 7th	International issue in English **Lab & Diagnostics of the Future,** April 7th, Stockholm
2	May 16th	April 25th	**New Updates in Drug Formulation & Bioavailability,** Sept 6th, Copenhagen **The Future of Swedish & Danish Life Science,** Sept 7th, Lund
3	Sept 15th	Aug 25th	**Bioscience – Research & Diagnostics through Innovative Technologies,** Nov 8th, Stockholm **Pharma Outsourcing – Find the right partner,** Dec 1st, Stockholm
4	Nov 30th	Nov 9th	**New Horizons in Biologics & Bioprocessing,** Dec 15th, Stockholm

* The magazine will be handed out to all delegates at associated event in addition to the regular subscribers. Hence the circulation is extended with 120-2.000 copies.

Adverts format & prices

SEK 71.500 | SEK 35.200 | SEK 26.200 | SEK 26.200

Register for our free newsletter on lifesciencesweden.se

Special format cover

SEK 37.200

Special format advert page



SEK 14.900
SEK 14.900
SEK 18.100 page 3 (horizontal format)

Company presentation in The Swedish Life Science Industry Guide (see page 4 for more info) SEK 16.500/year

Inserts
Unbound supplement,
max 175x245 mm, max 40 gram
2 pages SEK 29.900
4 pages SEK 32.500
8 pages SEK 35.800

BE A **LABORATORY** SUPERHERO

RUN 3 DSC SAMPLES AT ONCE

3 Samples

1 Run

0 Compromise

3 samples in **1 test**...The **New Discovery X3 DSC**

DISCOVER the POWER of **3**

TA® tainstruments.com

What science can do

AstraZeneca

At AstraZeneca, we have a strong belief in what science can do. That it can change the way we treat serious diseases. Through our innovative medicines used by millions of people around the world, we can help improve and prolong people's lives.

We operate in more than 100 countries and our business covers the entire chain of pharmaceuticals, from discovery and development to manufacturing, marketing and distribution. AstraZeneca is one of Sweden's most important export companies and has in total 7400 employees at two sites in Sweden. Gothenburg is home to one of AstraZeneca's most important global research facilities and the company's largest production facility is located in Södertälje.

Next generation therapeutics
Advancements in biotechnology have expanded our toolkit of drug modalities. This provides an opportunity to design therapeutics for disease mechanisms previously considered difficult, if not impossible, to target and enables our scientists to pioneer new approaches to drug discovery.

AstraZeneca
151 85 Södertälje
www.astrazeneca.se

SE-9432-12-21-AZ